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ABSTRACT
Alzheimer’s disease (AD) is characterized by amyloid β plaques and neurofibrillary tau
tangles (NFTs). While research has demonstrated amyloid pathology occurs prior to tau
pathology, or tauopathy, tau has proven to be more toxic. Tauopathy is associated with cognitive
declines and neurodegeneration. These findings have highlighted the importance of further
understanding tauopathy. In the progression of tauopathy, there is an observable immune
response that can be measured by glial cells such as microglia. Activated microglia are known to
exacerbate tauopathy rather than reducing the pathology. Research has indicated that with
increased age there is an increased risk for AD-related tauopathy and a more reactive, or primed,
immune response. Therefore, it is important to further understand how tauopathy and immune
markers change in respect to age to potentially identify critical periods that might be
advantageous for future interventions. This dissertation is aimed at understanding the effects of
age and genetic mutant variants of tau in different animal models of tauopathy over three
different studies.
In study one, a commonly used transgenic model of tauopathy, rTg4510, was studied to
examine how markers of tauopathy and tauopathy-related pathology differ over the life course.
Regression analyses were conducted to determine the best models of fit (linear vs non-linear
models of fit) for each marker. Results indicated that not all the markers of pathology in this
model progress at the same rate or in the same manner. However, there was an overall increase
in pathological events with increased age; especially in histological sections and the detergent
insoluble homogenate fraction that contains pathological aggregates.
viii

In study two, age differences between young, middle-aged, and old animals that received
either AAV9 GFP or AAV9 tauP301L intracranial injections were examined. Two-way ANOVAs
and two-way repeated measures ANOVAs were conducted to determine group differences on
measures of tauopathy, tauopathy-related markers of pathology including immune activation and
neurodegeneration, and behavioral assessments of motor and cognitive impairments. These
results indicated the old mice had higher levels of early phosphorylated tau, neurofibrillary tau
tangles (NFTs), and reactive immune activation. Behavioral assessments evidenced a reduction
in performance in the old animals irrespective of the injection group. However, only the younger
GFP injected mice (young and middle-aged) were able to demonstrate mastery of the memory
task. The old GFP and tauP301L injected mice were not able to achieve the historical learning
criterion in the memory task.
In study three, viral constructs expressing different tau variants were employed including,
AAV9 tauP301L, AAV9 tauR406W, AAV9 tauwild-type , and AAV9 GFP intracranial injections were
conducted in middle aged mice to identify whether tau mutations associated with human disease
could produce a translational model of tauopathy. One-way ANOVAs and one-way repeated
measures ANOVAs were conducted for measures of tauopathy, tauopathy-related pathology
including immune activation and neurodegeneration, and behavioral assessments to determine
any motor or cognitive deficits. The results indicated that both tauP301L and tauwild-type created
models of tauopathy that include declines in a behavioral memory task. However, these two
viruses displayed different mechanisms that warrant further investigation. TauP301L demonstrated
the highest levels of insoluble tau and NFTs, similar to the rTg4510 model, while tauwild-type had
the highest levels of histological phosphorylated tau, soluble tau, and exhibited the greatest
amount of hippocampal atrophy.
ix

This body of work demonstrates the importance of age in both transgenic and viral
models of tauopathy. As demonstrated by studies one and two, there are changes that occur in
animal models that can demonstrate a progression of pathology. This progression is critical as
translational models of AD-related tauopathy are imperative for furthering the knowledge of tau
and potential treatments. Additionally, the viral models validate the need to understand earlier
events in the progression of pathology. The tauP301L and tauwild-type viruses both modeled
tauopathy. However, these viruses, did so in distinct ways that warrant further investigation to
determine if there are differences early in the progression of pathology that are driving the
observed differences found in age and/or viral differences.

x

CHAPTER ONE:
BACKGROUND
The increase in the aging population is in part due to the medical advancements that have
allowed for the identification of treatments and preventative approaches for many of the leading
causes of death (Johnson, Hayes, Brown, Hoo, & Ethier, 2014). Currently, Alzheimer’s disease
(AD) is the sixth leading cause of death in the United States and lacks any FDA approved
treatments to reverse or halt AD pathology (Cummings, Lee, Ritter, Sabbagh, & Zhong, 2019;
Cummings, Morstorf, & Zhong, 2014; Huang, Chao, & Hu, 2020). There are two subgroups of
AD, familial AD, and sporadic AD. Most AD cases are sporadic AD where there is no confirmed
etiological cause compared to familial AD that is linked to genetic mutations. Currently,
increased age is the greatest known risk factor for a sporadic AD diagnosis. While there are no
disease-modifying treatments, research has identified key biological indicators of AD that
include extracellular amyloid β plaques and intracellular neurofibrillary tau tangles (NFTs).
Research has indicated amyloid pathology is one of the early events in the progression of
AD (Bush, Beyreuther, & Masters, 1992; Podlisny, Tolan, & Selkoe, 1991; Selkoe, 1991;
Tanaka et al., 1992). One of the first mutations associated with familial AD was the genetic
mutation of the amyloid precursor protein that increases production of amyloid β plaques by
increasing the length of the amyloid β peptide (Goate et al., 1991). These findings contributed to
the amyloid cascade hypothesis that posits the production of amyloid β is the pivotal event to AD
pathology (Hardy & Higgins, 1992). It has been discovered that the pathological changes in
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amyloid β can occur as early as 20 years prior to the onset of symptoms (H. Braak, Braak, Bohl,
& Reintjes, 1996; Villemagne et al., 2008). Historically, this has led many clinical trials to focus
on the reduction and clearance of amyloid β (Huang et al., 2020). Surprisingly, these clinical
trials have demonstrated not only limited cognitive improvements, but limited amyloid clearance
and prevention of further degeneration (Delrieu, Ousset, Voisin, & Vellas, 2014; Karran &
Hardy, 2014; Salloway et al., 2009; Salloway et al., 2014). Given the demonstrated lack of
overall efficacy of these clinical trials, some researchers have suggested future efforts to focus on
additional aspects of the disease such as tau (Kametani & Hasegawa, 2018; Ricciarelli & Fedele,
2017). Numerous studies have identified that tau pathology, or tauopathy, is strongly related to
neurodegeneration and cognitive deficits (Bejanin et al., 2017; Gordon et al., 2018; Hanseeuw et
al., 2019; Malpas, Sharmin, & Kalincik, 2020). This supports the importance of studies to further
understand the mechanisms of tauopathy.
Tau
Tau is a necessary microtubule-associated protein that is primarily located in the axon of
neurons. Tau is crucial for the stabilization of the cytoskeleton, aiding in axonal transportation,
and synaptic plasticity (Avila, Lucas, Perez, & Hernandez, 2004; Drubin & Kirschner, 1986; Y.
Wang & Mandelkow, 2015). There are six isoforms of tau (Buée, Bussiere, Buée-Scherrer,
Delacourte, & Hof, 2000). These different isoforms are generated by alternative splicing of
exons 2, 3, and 10 of the human tau MAPT gene. Exons 2 and 3 are located in the amino
terminus projection domain. The projection domain functionality determines the distance
between the microtubules (Chen, Kanai, Cowan, & Hirokawa, 1992). The alternate splicing for
the projection domain includes the presence of both exons 2 and 3, referred to as N1 and N2
(2N), N1 only (1N), or lacks both N1 and N2 (0N). Exon 10 is located in the microtubule
2

binding domain and is responsible for binding to the microtubules and to other proteins (F. Liu &
Gong, 2008). Alternate splicing of exon 10 can result in either 3 (3R) or 4 (4R) microtubule
binding repeat domains. Many of the detrimental mutations observed in tauopathies other than
AD occur in exon 10 (F. Liu & Gong, 2008). In AD, both 3R and 4R tau have been observed in
NFTs (Espinoza, De Silva, Dickson, & Davies, 2008; Rosenberg, Ross, Feinstein, Feinstein, &
Israelachvili, 2008). Moreover, there appears to be a shift in the 4R to 3R ratio in the progression
of AD, wherein the 4R tau predominance transitions to 3R (F. Liu & Gong, 2008; Uchihara,
2014).
Once tau is synthesized it can undergo a variety of post-translational modifications, but
the most widely studied in coordination with AD has been phosphorylation. While
phosphorylation is required for several different important biological mechanisms, when it
becomes hyperphosphorylated, tau often results in pathological conformational changes (Dubey,
Ratnakaran, & Koushika, 2015; Y. Wang & Mandelkow, 2015). These conformational changes
result in a severe reduction in tau’s binding affinity to the microtubules. With a reduction in
microtubule binding, tau begins to accumulate and migrate to the somatodendritic compartment
(Gendreau & Hall, 2013). In addition, hyperphosphorylated tau is more resistant to degradation
and has a propensity to sequester additional tau from the axon. Once additional tau is
sequestered, tau begins to form aggregates that are referred to as paired helical filaments (PHFs).
Research has indicated serine 396 as an important phosphorylation epitope of tau for the
formation of PHFs (Bramblett et al., 1993). As PHFs are resistant to degradation and continue to
aggregate, this results in the destabilization of the cytoskeleton and the formation of argyrophilic
NFTs (H. Braak, Alafuzoff, Arzberger, Kretzschmar, & Del Tredici, 2006). The structural
formation of NFTs contributes to cellular death as the neuron is no longer able to transport vital
3

material within the cell required for survival. Once the neuron dies, an extracellular “ghost”
tangle” is left behind that still retains argyrophilic properties (F. Braak, Braak, & Mandelkow,
1994; Endoh, Ogawara, Iwatsubo, Nakano, & Mori, 1993; Uchihara, 2014; Uchihara, Hara,
Nakamura, & Hirokawa, 2012).
Tau and Inflammation
In recent decades research has proven that the brain is not “immune privileged” as once
assumed. Aging research has identified there is an increase in the baseline inflammatory status
with increased age (Franceschi et al., 2000; Franceschi & Campisi, 2014; Franceschi et al.,
2007). This priming effect for pro-inflammatory mediators, generates more reactivity with age.
In addition, there are deficiencies in anti-inflammatory mechanisms with age, so it takes longer
for the body to recover from an inflammatory response. However, in age-related diseases such as
AD, inflammation is amplified by the chronic presence of pathology (Akiyama et al., 2000;
Nizami, Hall‐Roberts, Warrier, Cowley, & Di Daniel, 2019; F. Su, Bai, & Zhang, 2016; W. Y.
Wang, Tan, Yu, & Tan, 2015; Zhang, Li, Ng, & Song, 2015).
The cells responsible for the inflammatory immune response within the central nervous
system are glial cells. Two of the glial cell types that have been examined in relation to AD are
microglia and astrocytes. Microglia are constantly sampling the environment which allows them
to quickly respond to homeostatic changes. To respond to changes in the environment, microglia
recognize pathogens using pattern recognition receptors, activate phagocytic properties, and
modulate additional pro-inflammatory factors (i.e., cytokines and chemokines) (Boche, Perry, &
Nicoll, 2013; Norden & Godbout, 2013). Astrocytes release additional inflammation factors, but
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also respond to injury, maintain ionic concentrations within and outside the cell, and regulate the
endothelial cells of the blood brain barrier (Abbott, Rönnbäck, & Hansson, 2006; Walz, 2000).
Interestingly there appears to be a paradoxical relationship for inflammation and AD
pathology. Immune activation generally can stimulate amyloid β clearance, but has consistently
been reported to exacerbate tauopathy (Ghosh et al., 2013; Herber et al., 2007; Joly-Amado et
al., 2020; Lee et al., 2010). This paradoxical relationship highlights the importance of further
understanding tau in relation to inflammation.
Clinical Alzheimer’s Disease Tauopathy
AD tauopathy progresses in a temporal manner that begin in the transentorhinal cortex
and ultimately encompasses critical cortical and subcortical areas. The Braaks have defined six
stages of AD-related tauopathy (H. Braak & Braak, 1991; H. Braak & Braak, 1995). Stage I
includes the mild formations of NFTs in the transentorhinal cortex with NFTs spreading to the
hippocampal areas in Stage II. Stage III is classified by NFTs projecting to other cortical areas
and initial ghost tangles become evident in the transentorhinal areas. Stages IV and V entails
continued projections to cortical regions and an increase in NFT severity. In the final stage, ghost
tangles and NFTs are abundant throughout the cortical and subcortical areas coupled with
neuronal loss.
These stages have remained a significant classification as clinical imaging has validated
the stages (Davis, Schmitt, Wekstein, & Markesbery, 1999; Marquié et al., 2017; Schwarz et al.,
2016). Cognitive researchers have identified that tauopathy is closely related to cognitive deficits
(Swinford, Risacher, Charil, Schwarz, & Saykin, 2018). The most commonly reported cognitive
deficit is memory. However, years before substantial deficits in global memory and activities of
5

daily living are noticed, changes in episodic and spatial memory can be identified (Blennow, de
Leon, & Zetterberg; Dubois et al., 2007; Schindler et al., 2017; Villemagne et al., 2008; Wilson,
Leurgans, Boyle, & Bennett, 2011). Episodic and spatial memory are hippocampal dependent
constructs (Bäckman, Jones, Berger, Laukka, & Small, 2005; Burgess, Maguire, & O'Keefe,
2002; Glisky, 2007; Hedden, 2007; Serino & Riva, 2014). As evidenced by the Braak stages, the
hippocampus is one of the brain structures that is impacted early in AD related tauopathy (H.
Braak et al., 1996; H. Braak, Thal, Ghebremedhin, & Del Tredici, 2011). As the pathology
burden continues, the clinical symptomology does as well. Clinical AD symptoms progress to
retrograde amnesia, deficits in attention, executive function, language, and even motor function
in advanced stages (Brugger, Monsch, Salmon, & Butters, 1996; Faust & Balota, 1997; Hehman,
German, & Klein, 2005).
Animal Models of Tauopathy
Transgenic Models
Since biological pathology is evident many years before the onset of clinical symptoms, it
is important to understand the biological mechanisms that occur in prodromal stages of AD.
Therefore, animal models are commonly employed. One of the early tau transgenic lines was the
JPNL3 P301L lineage, where the pathology is driven by the mouse prion promoter (Lewis et al.,
2000). This lineage was formed after the identification of the 4R0N P301L tau mutation for
frontotemporal dementia and parkinsonism chromosome 17 (FTD-17) (Hutton et al., 1998).
Lewis et al. (2000) noted an increase of insoluble tau from 2 to 8 months of age, NFTs by 4.5
months, and evidence of inflammation. However, there was also pathology in the spinal cord
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resulting in hindlimb paralysis by 10 months of age. This is a large confound for both aging
studies and animal behavioral assessments.
In hopes of improving the JPNL3 P301L animal model, the rTg4510 line was created
(Ramsden et al., 2005; Santacruz et al., 2005). This is a bigenic line that is created from breading
a mouse that harbors a tetracycline-operon-responsive element upstream of the 4R0N P301L
mutation with another mouse containing the tetracycline-controlled transcriptional activator
downstream of the CaMKIIα (calcium calmodulin kinase II subunit alpha) promoter (Santacruz
et al., 2005). The tetracycline-controlled transcriptional activator allows for the suppression of
mutant tau expression with the treatment of doxycycline. The CaMKIIα promoter predominately
expresses pathology to the forebrain and cortex while preserving the spinal cord, and the animals
do not experience the hindlimb paralysis of the previous tau model (Dutschmann et al., 2010;
Santacruz et al., 2005). The seminal work by Ramsden et al. (2005) included time series
experiments up to 10 months of age. NFTs and memory impairments begin to accumulate as
early as 2.5 months , with cortical atrophy at 9 months. Furthermore, there was noted neuronal
loss, and astrocyte activation. At 16 months there was evidence of atrophy and a 30% reduction
in brain weight was noted. Further research has evidenced an upregulation of inflammatory
pathways for this model (H. Wang et al., 2018; Wes et al., 2014).
Viral Models
While transgenic models have proven to be instrumental for many research discoveries,
they generally produce an overabundance of pathology. For AD transgenic models, they
generally produce pathology early in life which more closely mimics familial AD and not
sporadic AD. Because the vast majority of AD diagnoses are sporadic and have no known
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genetic component, transgenic models have less translational value for sporadic AD. Therefore,
many researchers have employed the use of viral models of tauopathy. Many use adenoassociated viral vectors (AAV), which is a form of gene therapy that allows for the transfer of
selected viral constructs to a region of interest (Daya & Berns, 2008). AAV is part of the
parvovirus family but requires the presence of helper plasmids to ensure outer capsid assembly
and allows for viral replication. Because AAV has an open reading frame where genes of interest
can be inserted, it is commonly referred to as an empty cassette system. The open reading frame
is flanked by inverted terminal repeats that allows for the insertion of 4.5kb of genomic material
such as the gene of interest and any viral tags or regulatory elements that may enhance the viral
expression (Loeb, Cordier, Harris, Weitzman, & Hope, 1999; Naso, Tomkowicz, Perry, &
Strohl, 2017). There are many different AAV serotypes that target specific cells. AAV9 is a
commonly used serotype that has a preference for neurons especially following intracranial
injections (Dayton, Wang, & Klein, 2012).
Because of the preference for neuronal transduction, AAV9 has been used for the
construction of viral models of tauopathy (Mustroph, King, Klein, & Ramirez, 2012;
Vanderweyde et al., 2016) . Research conducted by X. Liu et al. (2017) evaluated intracranial
entorhinal cortex injections of AAV9 tauP301L and AAV9 green florescent protein (GFP) in three
month old male C57BL/6 mice that were incubated for six weeks. GFP is commonly used as a
control virus as this causes the infected cells to fluoresce green. There was evidence of tau
expression that encompassed the cortex and hippocampus including phosphorylated epitopes of
pSer199 and pSer396. Additionally, there was a reduction of neurons in the dente gyrus of the
hippocampus, reduction of synaptic density measured by PSD-95, and a decline in a behavioral
social transmitted food preference test (STFP). STFP is a hippocampal dependent food
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preference test. Cook et al. (2015) examined differences between AAV1 tauP301L and the
rTg4510 transgenic line to ensure tau expression. There was evidence of robust tau expression
after 6 months of viral incubation after intracerebroventricular injections into newly born mouse
pups. Further analysis found evidence of phospho-tau epitopes pSer396/404, pSer202, and
pSer262/356. There were silver positive NFTs, with microglia and astrocyte activation when
compared to AAV1 GFP injection. Jaworski et al. (2009) employed the use of AAV1/2-TauP301L
and AAV1/2-Tauwild-type along with a control AAV1/2 GFP using intracerebral injections. There
was evidence that the tauP301L induced hippocampal thinning and both P301L and wild-type tau
groups had neuronal loss by 3 weeks. When examining tau expression and phospho-tau epitopes
including pSer202, pThr205, pThr231, pSer396, and pThr404 demonstrated that the AAV1/2
tauP301L had more tauopathy present when compared to tauwild-type. Furthermore, there was
evidence of microglia and astrocyte activation.
Using the background knowledge of current tauopathy research, this dissertation
examined both transgenic and viral models of tauopathy over three different studies.
Study One examined how markers of pathology differ over the life course of the
rTg4510 mouse model. To achieve this, tissues were collected from both male and female
rTg4510 mice aged from two to twenty months. Histological and biochemical measures include
markers of tauopathy, microglia, astrocytes, and indicators of neurodegeneration.
Study Two investigated the effect of age on a viral method of tauopathy after the
induction AAV9 GFP and AAV9 tauP301L in 8-, 12-, and 16-month old male and female
C57BL/6 mice. Injections were administered to bilateral hippocampi and anterior cortices.
Behavioral assessments were conducted to evaluate any evidence of cognitive impairments at 3.5
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months of viral incubation. Tissues were collected at 4 months and analyzed to evaluate the
effect of age of onset on markers of tauopathy, immune activation, and neurodegeneration.
Study Three explored effects of different AAV9 tau variants that included tauwild-type,
tauP301L, and tauR406W with AAV9 GFP as a control virus. This was conducted to determine if one
of these constructs may be more of a translational model of AD tauopathy. Injections were
administered bilaterally to hippocampi and anterior cortices. At 3.5 months of viral incubation,
behavioral assessments were conducted to determine any evidence of cognitive impairment
based on the tau variant injection. Tissues were collected at 4 months post injection and analyses
were conducted to determine group differences based on tau variant injection on measures of
tauopathy, immune activation, and neurodegeneration.
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CHAPTER TWO:
AGE SERIES EXAMINATION OF THE rTG4510 MODEL OF TAUOPATHY
Introduction
Tauopathy is one of the hallmark features of Alzheimer’s Disease (AD) and is closely
related to cognitive decline and neuronal loss (Bejanin et al., 2017; Malpas et al., 2020). To date,
age still proves to be the greatest risk factor for AD-related tauopathy and increased tau burden.
In the progression of tauopathy, it is evident that there are measurable changes early in the
phosphorylation process and research indicates this can be measured by the phospho-tau epitopes
of serine199 and serine202 (Luna-Munoz, Chavez-Macias, Garcia-Sierra, & Mena, 2007; J. H.
Su, Cummings, & Cotman, 1996). As pathology increases in severity, further phosphorylation
occurs and the phospho-tau serine396 epitope (Kimura et al., 1996; Mondragón‐Rodríguez,
Perry, Luna‐Muñoz, Acevedo‐Aquino, & Williams, 2014). This later phospho-tau epitope has
proven to be a critical residue for the formation of paired helical filaments (PHFs) which is an
intermediary progression to the formation of neurofibrillary tau tangles (NFTs) (Bramblett et al.,
1993).
Furthermore, in the aging process where there is an increased risk for AD pathology,
there is also a general increase in pro-inflammatory homeostatic balance (Franceschi & Campisi,
2014). Research has demonstrated that this increase in inflammation that has proven to increase
tau burden (Ghosh et al., 2013; Herber et al., 2007; Lee et al., 2010). Therefore, the examination
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of immune activation with age is an important aspect to evaluate when examining tauopathy as
this may be an advantageous avenue for future interventions.
The rTg4510 line has been extensively used as a model of tauopathy. This line expresses
the 4R0N tau P301L mutation and expresses pathology in the cortex and hippocampus
(Santacruz et al., 2005). Previous research has demonstrated that rTg4510 line exhibits agedependent neurofibrillary tau tangles (NFTs), neuronal loss, behavioral impairments, and an
inflammatory response (Ramsden et al., 2005; Santacruz et al., 2005). The seminal work of this
transgenic line included short time course studies of tauopathy up to approximately 10 months of
age (Ramsden et al., 2005; Santacruz et al., 2005). These studies observed NFTs as early at 2.5
months and significant reductions in brain weight by 5 months. Additional research has extended
age differences to 13 and 15 months that indicate increased pathology with age (Blackmore et
al., 2017; Ludvigson, Luebke, Lewis, & Peters, 2011). When examining age in the rTg4510 line,
it is important to note that Ramsden et al. (2005) evidenced that this line can survive up to 20
months of age.
While there has been a general consensus of an increase of NFTs with age in the rTg4510
line, work by Dickey et al. (2009) found that not all phospho-tau epitopes increase in a linear
fashion as demonstrated by an age series examination up to 10 months of age. This leads to
further investigation to understand how multiple markers of varying degrees of tauopathy
severity differs over the life course in respect to important hallmarks of tauopathy including
phosphorylated tau epitopes, NFTs, inflammation, and indicators of neuronal loss and atrophy.
To date, no study has provided a detailed age series examination of the rTg4510 line that has
extended to 20 months of age. Furthermore, this is the first study to compare different models of
fit to determine how rTg4510 pathology changes at increasing ages. Therefore, the purpose of
12

this study is to address how these critical measures of tauopathy differ at increasing age points in
three aims.
Aim One: To investigate how markers of tauopathy differ at increasing ages, including
measures of total tau, early and late indicators of phosphorylation, and NFTs up to 20 months of
age.
Aim one hypotheses: Indicators of tauopathy including total tau, early and late
phosphorylated tau, and NFTs will be most severe in the 20-month old mice.
Aim Two: To determine how markers of tau-related pathology, including immune
activation and neurodegeneration differ at increasing ages.
Aim two hypotheses: Given the prior research of increasing inflammation with age, there
will be an increase in inflammation with increased age. Furthermore, it is expected that there will
be a continued linear decrease in brain weight, hippocampal volume, and synaptic density based
on the atrophy observed in the early studies of this model.
Aim Three: To examine how changes in tauopathy and other markers associated with
tauopathy are related.
Aim three hypotheses: Indicators of tauopathy will be positively related to inflammation
as the research indicates tau burden increases with inflammation. Furthermore, tau with be
negatively related to neurodegeneration because we know tau is associated with degeneration
and this will be most severe at 20 months of age.
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Method
Animals
The rTg4510 line is a bigenic line bred by crossing one mouse line that contains both the
4R0N P301L tau mutation and the tetracycline-operon responsive element with another line that
expresses the tetracycline-controlled transcriptional activator that is driven by the CaMKIIα
promoter. This promoter restricts tauopathy predominately to the forebrain and extends to the
rest of the cortex and hippocampus. This avoids spinal expression and subsequent paralysis seen
in other mutant tau transgenic lines. Both male (n=27) and female (n=26) rTg4510 mice were
used. Some mice born in this breeding lack both transgenes and are referred to as non-transgenic
(ntg). Ntg mice were used as negative controls. Animals were kept on a 12-hour light cycle and
were provided food water ad libitum. All animal protocols were conducted and approved by the
Institutional Animal Care and Use Committee of the University of South Florida.
Tissue Collection
Mice were aged between 52 and 610 days of age until tissue collection. The mice were
anesthetized with 0.1mL/10g Somnasol (0.25mL in 10mL of H2O) and placed on a heating pad
to maintain body heat to reduce tau phosphorylation caused by decreased body temperature
during anesthesia (Planel et al., 2007). Animals were perfused transcardially with 25mL of 0.9%
normal saline solution. Once the animals were perfused, the brains were immediately extracted.
The brains were placed on an iced stage and the right hemisphere was dissected into the anterior
region of the cortex (ACX), posterior region of the cortex (PCX), and the hippocampus (HPC).
The brain regions were immediately frozen on dry ice. Brain region specimens were stored at 14

80˚C until homogenization for biochemical analysis. The left hemisphere was immediately
immersed in 20mL of freshly prepared 4% paraformaldehyde (pH 7.4) for 24 hours at 4˚C. After
24 hours, the left hemispheres were cryoprotected, where each brain was placed successively in
10, 20, and 30% sucrose for 24 hours. The brain hemispheres were stored at 4˚C until sectioned.
Brains were horizontally sectioned with a freezing microtome at a 25μm thickness and placed
into Dulbecco’s phosphate buffered saline with 10 mM sodium azide solution (7.4 pH) except
for every 8th section that was sectioned at 50μm thickness for hippocampal volumetric analysis.
Brain Homogenization and Biochemical Analysis
The PCX was added to a 10v/w RIPA (50mM Tris-Cl, 150nM NaCl,1% NP40, 0.1%
SDS, 0.05% sodium deoxycholate) buffer with protease inhibitor cocktail (Sigma Aldrich, St.
Louis, MO, USA; Cat. No. P8340), phenylmethanesulfonyl fluoride (Sigma Aldrich, St. Louis,
MO, USA; Cat. No. P7626), and phosphate inhibitor cocktails II and III (Sigma Aldrich, St.
Louis, MO, USA; Cat. Nos. P5726 & P0044, respectively). Samples were homogenized first by a
rotating mechanical pestle and then by sonication. Once sonicated, a consistent aliquot was
removed from each sample and centrifuged at 50,000g for 1 hour at 4˚C. The remaining crude
homogenate was stored at -80 ˚C until analysis. Once the centrifugation was complete, the
supernatant was removed and stored as the detergent soluble fraction, and the detergent insoluble
pellet was kept for formic acid processing. Formic acid processing was conducted by adding a
fifth of the total sample volume of 70% formic acid to each pellet and homogenized by a rotating
mechanical pestle and sonicated again. After sonication, the samples were gently rotated for 30
minutes. 15.1M NaOH was added to neutralize formic acid samples. Once neutralized, 1M TrisBase (pH 7.6) was added to a 1:2 ratio to the homogenate volume. Individual insoluble samples
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were adjusted to pH of 7. Protein concentrations for crude, supernatant, and formic acid fractions
were determined by Pierce BCA protein assays.
For western blot analysis, equal amounts of protein were added to each well (10ug/well)
on Bio-Rad 4-20% polyacrylamide Criterion™ TGX Stain-Free Gels (Bio-Rad, Hercules, Cali;
Cat. No. 5678094) and electrophoresed with tris glycine running buffer (Bio-Rad, Hercules, Cali;
Cat. No. 1610732). Once the run was complete, gels were placed on Bio-Rad ChemiDoc MP
imaging trays and were UV activated. UV activation was completed by using the imager’s UV
activation function, which allows the compounds within the gel to bind to the proteins in the
sample to display the total protein to be quantified for normalization of small differences in
protein loading. After UV activation, the gels were transferred to 0.2μm midi nitrocellulose
membranes (Bio-Rad, Hercules, Cali; Cat. No.1704159) using Bio-Rad Trans-Turbo Transfer
System (Bio-Rad, Hercules, Cali; Cat. No.12003154). Membranes were blocked in 5% nonfat
dry milk blocking buffer for 45 minutes and then incubated in the respective primary antibody
for overnight incubation at 4˚C (Table 1). The following morning membranes were washed 3
times in tris buffered saline (TBS, (50 mM Tris-Cl, pH 7.6; 150 mM NaCl, pH 7.6) plus 0.07%
tween-20 for 10 minutes per wash and then incubated in the corresponding secondary antibody
for 1 hour. Finally, the membranes were washed 3 additional times in TBS+0.07% tween-20 for
10 minutes. Blots were imaged using Bio-Rad ChemiDoc MP. The total lane of positive antigen
signal was normalized to the total protein.
Histopathology
Tissues from both rTg4510 and ntg mice were placed in free-floating multi-sample
staining trays for each marker. The trays were placed in an endogenous peroxidase blocking
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solution (10% methanol, 3%H2O2 in PBS). The tissues were washed 3 times with PBS and then
placed in permeabilizing solution (0.2% lysine, 1%Trition X100, 4% normal goat serum in PBS).
Tissues were then incubated overnight in the appropriate antibody (Table 1). The following
morning, tissues were washed with PBS and incubated for 2 hours in the corresponding
biotinylated secondary antibody. This step was excluded if the primary antibody was
biotinylated. After the two-hour incubation period, tissues were washed with PBS and placed in
Vectastain® Elite® ABC kit solution (Vector Laboratories, Burlingame, CA; cat. no. PK-6100)
to enhance the enzyme complex. Again, tissues were washed with PBS for 2 washes and the final
wash was in TBS. Following the TBS wash, tissues were placed in a color development solution
(0.05% DAB, 0.5% Ni2+, .03% H2O2) for 5 minutes. To stop color development, tissues were
washed with TBS for one wash and then 2 PBS washes. Upon the completion of staining, tissues
were mounted on microscope slides (Fisher Scientific, Waltham, MA; cat. no. 1255015),
dehydrated, and cover slipped with DPX mounting medium (Electron Microscopy Sciences,
Hatfield, PA; cat. no. 13512).
For Gallyas and cresyl violet staining, tissue sections were first mounted on microscope
slides and dried overnight. Gallyas staining is a silver stain that identifies NFTs (Uchihara,
2007). On the day of Gallyas staining, sections were briefly rehydrated and then placed in a
pretreatment solution (5% periodic acid). After a series of washes, the slides were immersed in a
silver enhancing solution (10% potassium iodide, 4%NaOH, 0.035% silver nitrate) for one
minute before incubating for 10 minutes in a 0.5% acetic acid solution. Slides were then placed
in a working developer solution (2.5% sodium carbonate, 0.1% ammonium nitrate, 0.1% silver
nitrate, 0.5% tungstosilic acid, 0.2% formaldehyde) for approximately 10 minutes. Upon
development, slides were washed with 0.5% acetic acid. Then slides were immersed in a gold
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toning solution (0.1% gold chloride solution) followed by an additional water wash. Then slides
were incubated in a solution to remove traces of unconjugated silver salts (0.1% sodium
thiosulphate solution) and a final water wash. Slides were immediately dehydrated and
coverslipped.
The cresyl violet stain was conducted on pre-mounted 50μm tissues. On the day of the
stain, slides were briefly rehydrated and then place in a 0.05% cresyl violet dye solution. After
staining, slides were briefly placed in an acetic acid water solution (pH 3.5) and rinsed in water.
Slides were then dehydrated and coverslipped with DPX mounting medium (Electronic
Microscopy Sciences Cat. No. 13512). Once the DPX was dried, slides were scanned using
ZEISS Axio Scan.Z1. Scanned slides were analyzed using NearCyte tissue analysis IAE software
(created by Andrew Lesniak). The cortex and hippocampus regions were identified and
immunopositive pixels above a user-defined threshold were measured. The threshold parameters
were derived using several sections with light and dark staining and held constant throughout the
remaining analysis. The fraction of the total region occupied by immunopositive pixels was
calculated. The values for each slide were then averaged together and for each region (ACX,
PCX, and HPC). Cresyl violet staining was conducted to measure hippocampal volume using the
method of Cavalieri.
Statistical Analyses
Statistical analyses were conducted using IBM SPSS Statistics 25 (Armonk, New York,
USA) and figures were created with GraphPad Prism 8 (La Jolla, CA, USA). The average of
fractional positive stained area for immunohistochemistry, Gallyas staining, hippocampal
volume, and western signal intensities normalized to total protein were z-scored to be able to
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compare across methodologies. Any data points that were greater than 3 standard deviations
from the mean were considered statistical outliers and removed from analysis. Only four
datapoints were excluded and this includes one for detergent insoluble total tau (HT7), detergent
insoluble pSer199/202-tau, histological total tau (HT7), and histological pSer396-tau. Regression
analyses were used to compare linear, quadratic, and cubic regressions to determine the best
model of fit for each marker throughout the lifespan of rTg4510 mice. The F change statistic was
used to determine significant differences between linear, quadratic, and cubic models of fit. In
addition, R2 was used to determine the variance explained by age. Furthermore, Pearson
correlations were used to determine the relationship between histological tau markers with
inflammatory and neurodegenerative markers. To determine if any significant correlations were
influenced due to the markers being largely age-dependent, partial correlations were conducted
to control for age.
Results
Aim One: How Markers of Tauopathy Differ with Increased Age
Neurofibrillary tangles
As the data from different markers against age in the rTg4510 mice were plotted, it was
evident that not all markers had linear trajectories. As a result, it was decided to contrast linear
equations with quadratic and cubic fit equations to determine if the nonlinear fits were
statistically superior. For Gallyas staining, a silver stain believed to detect NFTs, all three models
of fit were significant (linear, F(1,36) = 89.267, p < .001; R2 = .713, quadratic, F(2,35) = 45.004,
p < .001; R2 = .720, and cubic, F(3,34) = 29.878, p < .001; R2 = .725). All three models of fit and
the individual data points are included in Figure 1. The nonlinear fits failed to improve upon the
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linear model (quadratic (F change (1,35) = .925, p = .343) and cubic (F change (1,35) = 1.130, p
= .295). Notably, Gallyas was the marker that had the most variance explained by age (R2 =
.713). Because the linear fit worked as well as the curvilinear models, it is believed that there is a
linear increase in Gallyas staining with age in the rTg4510 model.
Histological tau
For histological tau markers (Figure 2), there was an increase in the amount of staining
across the markers until approximately twelve months of age. At twelve months, HT7 staining, a
marker of total tau, peaks and then begins to decline. The linear model of fit failed to reach
significance, (F(1,31) = 2.586, p = .118), while the non-linear models were significant
(quadratic, (F(2,30) = 9.879, p = .001; R2 = .397 and cubic, (F(3,29) = 6.367, p = .002; R2 =
.397). Further analysis found that the non-linear models were not significantly different (p =
.971). In contrast to HT7, pSer396-tau exhibited a plateau at twelve months of age. Even though
all three models of fit were significant (linear, F(1,33) = 15.111, p < .001; R2 = .314, quadratic,
F(2,32) = 12.078, p < .001; R2 = .430, and cubic. (F(3,31) = 7.816, p = .001; R2 = .431), the nonlinear models of fit (quadratic, F change (1,32) = 6.518, p = .016) and cubic, F change (1,32) =
6.520, p = .016) significantly improved the linear model. A further examination verified that the
nonlinear models of fit were not significantly different (p = .871), thus the relationship was
concluded to be quadratic. This model of fit supported the plateau observed at twelve months of
age for histological pSer396.
In contrast, all three models of fit (linear, F(1,32) = 11.868, p = .002; R2 = .271,
quadratic, F(2,31) = 6.774, p = .004; R2 = .304), and cubic, F(3,30) = 4.370, p = .011; R2 = .304)
were significant for AT8 (pSer199, 202-tau). While all models were significant, the nonlinear
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models of fit (quadratic, F change (1,31) = 1.495, p = .231 and cubic, F change (1,31) = 1.466, p
= .235) failed to improve the linear model. This model indicates an increasing linear relationship
with age.
Detergent soluble tau
When analyzing the supernatant detergent soluble tau markers measured by western blot
(Figure 3), it was evident that pSer396-tau plateaued at approximately twelve months of age,
resembling histological pSer396-tau. All three models of fit (linear, F(1,47) = 24.115, p < .001;
R2 = .339, quadratic, F(2,46) = 16.935, p < .001; R2 = .424, and cubic, F(3,45) = 11.515, p <
.001; R2 = .434), were significant, with the non-linear models of fit improving the model
(quadratic (F change (1,46) = 6.787, p = .012) and cubic (F change (1,46) = 7.360, p = .009).
With further analysis, the non-linear models were not significantly different from one another (p
= .373). In comparison to histological HT7 a measurement of total tau, detergent soluble HT7
decreased linearly with age, (F(1,47) = 4.433, p = .041). This linear relationship is demonstrated
by the nonlinear models of fit failing to reach significance (quadratic, F(2,46)= 2.384, p=.103; R2
= .094 and cubic, F(3,45) = 2.423, p = .078; R2 = .139). Soluble pSer199/202-tau shares a
phosphorylated epitope with histological AT8. Like AT8, all three models of fit were significant
for detergent soluble pSer199/202-tau (linear, F(1,45) = 50.012, p < .001; R2 = .526, quadratic,
F(2,44) = 24.453, p < .001; R2 = .526, and cubic, F(3,43) = 19.985, p < .001; R2 = .582).
Additionally, the nonlinear models failed to improve the linear model (quadratic, F change (1,44)
= 5.789, p = .958, and cubic, F change (1,44) = .120, p = .731). However, in contrast with
histological AT8, soluble pSer199/202-tau declined with age.
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Detergent insoluble tau
When examining the detergent insoluble (formic acid) fraction, tau markers measured by
western blot (Figure 4), the markers changed in a similar manner as histological markers. For
insoluble HT7, the linear model was not significant (F(1,47) = 2.896, p = .095); whereas, both
the non-linear models (quadratic, F(2,46) = 6.799, p = .003; R2 = .228, and cubic, F(3,44) =
4.437, p = .008; R2 = .228) were significant. Insoluble HT7 resembled histological HT7, where
the marker peaked at twelve months of age and then declined. Correlational analysis revealed a
positive significant relationship between histological and insoluble HT7 (r = .426, p = .024). In
contrast, for detergent soluble pSer199/202-tau all three models of fit were significant (linear,
F(1,48) = 10.180, p = .003; R2 = .175, quadratic, F(2,47) = 5.033, p = .010; R2 = .176, and cubic,
F(3,46) = 3.318, p = .028; R2 = .178), with the nonlinear fits failed to improve the linear model
(quadratic, F change(1,47) = 0.080, p = .779 and cubic, F change(1,47) = 0.101, p = .752).
Insoluble pSer199/202-tau was comparable to histological AT8, such that, they both increased
linearly with age (r = .436, p = .016). For insoluble pSer396-tau, all three models of fit were
significant (linear, F(1,48) = 37.596, p < .001; R 2= .439, quadratic, F(2,47) = 19.001, p < .001;
R2 = .447, and cubic, F(3,46) = 12.858, p < .001; R2 = .456). However, both the quadratic (F
change (1,47) = .667, p = .418) and cubic (F change (1,47) = .849, p = .362) models failed to
improve upon the linear model. This statistical analysis confirmed an increasing linear
relationship with age for detergent insoluble pSer396-tau. Even though the histological pSer396
plateaued, and insoluble pSer396 continued to increase with age, the markers exhibited a positive
correlation (r = .397, p = .027).
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Aim Two: How Additional Tau-Associated Markers of Pathology Differ with
Increased Age
Inflammation
When inflammation markers were analyzed, there was a general increase with age (see
Figure 5). For histological CD45, all of the models of fit (linear, F(1,44) = 34.366, p < .001; R2 =
.439, quadratic, F(2,43) = 18.898, p < .001; R2 = .468, and cubic, F(3,42) = 14.802, p < .001; R2
= .514) were significant. However, both the nonlinear models (quadratic, F change (1,43) =
2.365, p = .131 and cubic, F change (1,43) = 3.194, p = .081) failed to significantly improve the
model fit. Histological Iba-1 was comparable to CD45, where all models were significant (linear,
F(1,40) = 53.298, p < .001; R2 = .571, quadratic, F(2,39) = 26.646, p < .001; R2 = .577, and
cubic, F(3,38) = 17.718, p < .001; R2 = .583) yet the nonlinear models (quadratic, F change
(1,39) = .569, p = .455 and cubic, F change (1,39) = .419, p = .521) failed to improve the model
fit. Similar to the previous markers, histological MHCII also had significant models of fit across
linear (F(1,34) = 18.214, p < .001; R2 = .349), quadratic, (F(2,33) = 10.058, p < .001; R2 = .379),
and cubic (F(3,32) = 8.089, p < .001; R2 = .431) models. When the differences were examined,
the quadratic (F change (1,30) = .506, p =.483) and cubic (F change (1,30) = .014, p =.365)
models of fit failed to significantly improve the linear model. Once again, all three models of fit,
(linear (F(1,37) = 46.386, p < .001; R2 = .556, quadratic, F(2,36) = 33.260, p < .001; R2 = .649,
and cubic, F(3,35) = 21.905, p < .001; R2 = .652) were significant for histological GFAP.
However, unlike the other immune markers, the quadratic (F change (1,36) = 9.490, p = .004)
and cubic (F change (1,36) = 9.920, p = .003) models of fit significantly improved the linear
model. While GFAP increased with age like the microglia markers, there was an evident plateau
at approximately fourteen months of age.
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Neurodegeneration
Across several neurodegenerative markers, it is apparent there was neurodegeneration
with increased age (Figure 6). All three models of fit for brain weight were significant (linear,
F(1,58) = 13.263, p = .001; R2 = .186, quadratic, F(2,57) = 7.599, p = .001; R2 = .211, and cubic,
F(3,56) = 5.183, p = .003; R2 = .217). When comparisons between the linear and nonlinear
models of fit (quadratic, F change(1,57) = 1.762, p = .190, and cubic, F change (1,56) = .487, p =
.488) were conducted, it was evident that the nonlinear models failed to improve upon the linear
model. Just as with brain weight, the linear model of fit was significant for hippocampal volume,
(F(1,47) = 17.834, p < .001; R2 = .275) along with both nonlinear models of fit (quadratic,
F(2,46) = 9.351, p < .001; R2 = .289, and cubic, F(3,45) = 6.938, p = .001; R2 = .316. Both the
quadratic (F change (1,46)= .904, p =.347) and cubic, (F change (1,46) = 1.232, p =.273) models
failed to improve the model fit. Additionally, all models of fit were significant for histological
NeuN, (linear, F(1,42) = 32.920, p < .001; R2 = .439, quadratic, F(2,41) = 16.080, p < .001; R2 =
.440, and cubic, F(3,40) = 11.253, p < .001; R2 = .458), where the nonlinear models (quadratic, F
change (1,41) = .013, p = .909, and cubic, F change (1,41) = .067, p = .797) failed to improve the
model fit. While the linear model was significant for total crude homogenate PSD95, (F(1,47) =
95.239, p < .001; R2 = .670), both the nonlinear models (quadratic, F change(1,46 )= 19.978, p <
.001; R2 = .770, and cubic, F change(1,46) = 21.918, p < .001; R2 = .780) significantly improved
the model fit. However, the two models of nonlinear fits were not significantly different (p =
.151). This model fit exhibited a decline in PSD95 that plateaued at approximately twelve
months of age.
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Aim Three: The Relationship of Tauopathy with Tau-Related Pathology Across
Increased Ages
When the relationships between tau with inflammatory and neurodegenerative markers
were examined, there appeared to be many significant relationships (Table 2). However, the most
remarkable tau marker was Gallyas. Gallyas had moderate to strong positive (Iba-1, MHCII,
GFAP, and CD45) and negative (brain weight, NeuN, PSD95, and hippocampal volume)
correlations with both inflammation and degenerative markers. However, when controlling for
age in partial correlations, the significant relationships that were observed in the Pearson
correlations lost significance.
Discussion
The purpose of this study was to provide an extension of the age-series data of the
rTg4510 mouse line to 20 months of age. Furthermore, this study sought to examine how
markers of pathology differ over the life course in three different aims. The first aim addressed
how markers of tauopathy differ over the life course. This study demonstrated not all markers of
tauopathy in rTg4510 mouse model follow the same trajectory.
Of all the pathological tau markers, Gallyas staining was the marker that most
consistently increased in a linear fashion with age (r2 = 0.713). This is the marker associated the
most severe stage of tauopathy in the present study. Because NFTs are resistant to degradation,
they continue to accumulate throughout the progression of pathology. In the progression of
disease, the neuron eventually dies and there is evidence of a ghost tangle or the remnants of the
argyrophilic tau filaments that are left behind. (Ikeda, Haga, Oyanagi, Iritani, & Kosaka, 1992).
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Because the ghost tangles remain after neuronal death and retains the argyrophilic properties, it
is expected that Gallyas staining would continue to increase with age.
Similar to Gallyas, the insoluble forms of phospho-tau follow a pattern with a linear
increase over the lifespan. Because advanced tau formations and NFTs are resistant to
degradation, they do not readily solubilize in RIPA detergent in the homogenization process. So,
when the tissue homogenate is centrifuged, these formations remain in the detergent insoluble
fractions. Therefore, it would be expected for the detergent insoluble fraction to display more
pathological tau in a similar fashion as Gallyas staining.
When total tau was examined in the insoluble fraction, the marker appears to plateau and
then decrease, possibly due to reduced production of tau secondary to neuron loss in older ages.
In the soluble fraction total tau and pSer199/pSer202 tau decreased linearly which indicate that
these markers could be more readily degradable forms of tau, whereas the pSer396 tau plateaus
after a year of age implying some resistance to degradation. The histological markers appear to
reflect some combination of the soluble and insoluble tau levels. HT7 labeled total tau increases
early, but declines in later ages implying some accumulation, but a reduced rate of accumulation
and possible reduction in later ages as less tau monomers are being produced. The pSer396
marker increases early and plateaus, similar to the soluble protein fraction. The AT8 labeled
pSer202/pThr205-tau immunostaining resembles more of the insoluble pattern of
pSer199/pSer202-tau accumulation by western analysis.
Research has indicated that pSer199 and pSer202/pThr205 epitopes are believed to be
phosphorylated at an early stage of abnormal tau development, in what some consider a pretangle stage, while pSer396 becomes evident in middle to late stages of the disease as PHFs form
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and progress to NFTs (Augustinack, Schneider, Mandelkow, & Hyman, 2002; Kimura et al.,
1996; Luna-Munoz et al., 2007; Mondragón‐Rodríguez et al., 2014; J. H. Su et al., 1996).
Additional research has examined the progression of tauopathy in respect to age using the Braak
stages (H. Braak et al., 2011). The Braak stages are a series of six stages that define increasing
stages of pathology in the progression of AD tauopathy. When the epitopes of pSer202/pThr205
were examined, they peaked in the stages designated as a pre-tangle stage in middle-age,
whereas the most severe stages of pathology peak at the most advanced ages. Work by Koss et
al. (2016) continued an examination of tauopathy in respect to the Braak stages. Results found
that the severity of epitopes pSer199/202 and pThr205-tau staining peaked at an earlier stage of
pathology in comparison to the pSer396 epitope. The evidence of earlier pSer199 and/or
pSer202/pThr205 severity, and the later progression of pSer396 confirms the current study’s
findings of a progression of tauopathy of how some markers may be more resistant to
degradation.
The second aim of this study was to examine how markers of tau-associated pathology
including inflammation and neurodegeneration differ over the life course. Research shows that
inflammatory factors are upregulated in the rTg4510 model (H. Wang et al., 2018; Wes et al.,
2014). Our findings indicate the microglia markers continue to increase in a linear fashion,
whereas astrocytes increase but tapers off just after one year of age. When examining markers of
neurodegeneration, the present study found that the markers of neuronal staining by NeuN,
hippocampal volume, and brain weight decline linearly which is consistent with the early studies
of the model.
Aim three evaluated the relationships of tauopathy with tau-related pathology across the
life course. As Gallyas staining was the marker that had a consistent increase across the
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progression of pathology in the rTg4510 life course, there were strong relationships with the taurelated markers of pathology. The negative linear relationships for Gallyas staining and markers
of neurodegeneration are consistent with the argument that NFTs contribute to
neurodegeneration. With the apparent neuronal loss that is occurring in this model, this could be
responsible for the reductions observed for total tau. The reduction in neurons would inherently
reduce the amount of total tau production and could be the cause of the observed reduction of
degradable forms of tau. Therefore, demonstrating the current declines in some of the soluble
total tau whereas, more insoluble tau and NFTs continued to increase in the current study.
The relationships between later tau pathology (pSer396 and Gallyas staining) may be
indicative of two different relationship patterns in respect to inflammatory markers. As
demonstrated the microglia markers increase linearly, while astrocytes tend to taper off after a
year of age. It is possible that the astrocytes are responding to injury to the neurons as PHFs
grow in severity, whereas microglia may still be attempting to clear the ghost tangles. It is
important to note, that markers of tauopathy and tauopathy-related markers vary over the life
course. Therefore, because these markers are so intertwined with age, it is not too surprising that
when age is controlled for, the relationships loose significance.
Most of the time course studies of rTg4510 line examine younger ages than the present
study. The original research of the rTg4510 line by Santacruz et al. (2005) and Ramsden et al.
(2005) only extended the time course studies to 10 months of age. Additional work conducted by
Dickey et al. (2009) demonstrated non-linear phospho-tau accumulation in soluble protein
fractions, while the insoluble fraction increased linearly up to 10 months of age. For the most
part, these time points revealed linear increases in histological and insoluble protein measures.
When examining the present study’s data, there are similar findings for age-dependent increases
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at those time points. However, only when extending the time course longer can the impacts of
reduced tau production be observed. These findings are instrumental for the examination of the
progression of pathology using the rTg4510 model to identify at what ages these pathological
changes occur. These additional findings are beneficial as it provides a more detailed time course
examination that allow researchers to identify when in the life course would be most appropriate
to address future studies such as earlier targets before the formation of NFTs and substantial
neurodegeneration.
Recently the rTg4510 model has come under scrutiny from Gamache et al. (2019). This
research group identified that the transgene insertion of the P301L mutation disrupts the Fgf14
and five additional genes that are believed to contribute to the observed phenotype of the
rTg4510 model. Unfortunately, the present study was not able to examine the additional genes
that may have been disrupted; however, the scope of this study was to examine how markers of
pathology change with age.
In conclusion this study provided an extension of the age-series examinations of the
rTg4510 line that demonstrated important differences that emerge later in the life course. It is
evident that markers that are more implicated in progressed pathology continue to increase with
age. Moreover, this study highlighted the importance of how some of the more readily
degradable forms of tau decrease the over the life course. Therefore, this study identified
important considerations when evaluating markers of tauopathy in the rTg4510 mouse line at
later ages.
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Table 1.
Summary of Primary and Secondary Antibodies Used for Immunohistochemistry and Western Bots
Primary
Antibodies
HT7

Host

Mouse

Target

Source

Total Tau

Invitrogen
MN1000B
Invitrogen
MN1000

AT8

Mouse

Phosphorylated tau at
Serine 202 and
threonine 205
epitopes

pSer396

Rabbit

Phosphorylated tau at
the Serine 396
epitope

Anaspec AS
54977-025

Invitrogen
MN1020B

Dilution

Methodology

1:5k

IHC

1:10k

Western Blot

1:10k

IHC

1:30k

IHC

1:2k

Western Blot

I-A/I-E

Rat

Major
histocompatibility
complex II

BD Pharmingen
556999

1:5k

IHC

CD45

Rat

Microglia

Invitrogen MA180090

1:10k

IHC

Iba1

Rabbit

Microglia

Fuji 019-19741

1:5k

IHC

GFAP

Rabbit

Astrocyte

Dako Z0334

1:5k

IHC

NeuN

Mouse

Neurons

1:30k

IHC

PSD95

Rabbit

Presynaptic structural

1:1k

Western Blot

Millipore
MAB377b
Cell Signaling
2507S
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Table 1. (Continued)
pSer199/202
Secondary
Antibodies
Biotinylated
Anti-Rabbit
IgG
Biotinylated
Anti-Rat IgG
680cw AntiRabbit IgG
IR dye
800cw AntiMouse IgG
IR dye

Rabbit

Phosphorylated tau at
the serine 199 and
202 epitopes

Anaspec AS-5496

1:2k

Western Blot

Host

Target

Source

Dilution

Methodology

Conjugates to Rabbit
host primary
antibodies
Conjugates to Rat
host primary
antibodies

Vector
Laboratories
BA-1000
Vector
Laboratories
BA-9400

1:3k

IHC

1:3k

IHC

Goat

Conjugates to Rabbit
host primary
antibodies

LI-COR
Biosciences
926-32211

1:10k

Western Blot

Goat

Conjugates to Mouse
host primary
antibodies

LI-COR
Biosciences
926-32280

1:10k

Western Blot

Goat

Goat
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Figure 1. Gallyas staining increases linearly with age in Tg4510 mice. Brain sections from
mice ranging in age from 50 to 590 days were stained as described in methods. The average
area occupied by positive staining was combined for anterior cortex, posterior cortex, and
hippocampus. Results were then normalized by calculating z-scores to facilitate comparison
with other markers over the lifespan. The line of fit and standard error of the mean (shaded
area) for linear, quadratic, and cubic models of fit are shown.
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Figure 2. Best fit equations for four histological measurements of tau
deposition indicate different relationships with age. The line of fit and the
standard error of the mean (shaded) are shown. Brain sections from mice
ranging in age from 50 to 610 days were stained as described in methods.
The average area occupied by positive staining was combined for anterior
cortex, posterior cortex, and hippocampus. Results were then normalized
by calculating z-scores to facilitate comparison with other markers across
the lifespan.
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Figure 3. Best fit equations for three measurements of soluble tau indicate
different relationships with age. The line of fit and the standard error of the mean
(shaded) are shown. The posterior cortex was dissected, homogenized, and the
detergent soluble fraction isolated as described in methods. Tau variants were
measured by immunoblot after separation of proteins by electrophoresis (western
blots). Staining intensity was normalized by comparison to total protein. Results
were then converted to z-scores to facilitate comparison with other markers across
the lifespan.
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Figure 4. Best fit equations for three measurements of detergent insoluble tau
indicate different relationships with age. The line of fit and the standard error of
the mean (shaded) are shown. The posterior cortex was dissected, homogenized,
and the detergent insoluble fraction isolated and dissolved in formic acid as
described in methods. Tau variants were measured by immunoblot after separation
of proteins by electrophoresis (western blots). Immunostaining intensity was
normalized to total protein staining of the gel. Results were then converted to zscores to facilitate comparison with other markers across the lifespan.
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Standardized Positive Fractional Area (z-score)

Glial Markers with Increasing Age
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Figure 5. Best fit equations for four histological measurements of glial
activation indicate mostly linear increases with age. The line of fit and the
standard error of the mean (shaded) are shown. Brain sections from mice
ranging in age from 50 to 590 days were stained as described in methods. The
average area occupied by positive staining was combined for anterior cortex,
posterior cortex, and hippocampus. Results were then normalized by
calculating z-scores to facilitate comparison with other markers across the
lifespan.
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Degenerative Markers with Increasing Age
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Figure 6. Best fit equations for four measures of neurodegeneration indicate
mostly linear decreases with age. The line of fit and the standard error of the
mean (shaded) are shown. Brain weights were collected at necropsy.
Hippocampal volume was estimated using 8 sections through the entire region
by the method of Cavalieri. Brain sections from were stained for NeuN as
described in methods, and PSD-95 was measured in posterior cortical total
homogenates by immunoblot. Results were then normalized by calculating zscores to facilitate comparison with other markers across the lifespan (left axis)
with the exception of the brain weight, which is shown in mg wet weight (right
axis).
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Table 2.
Correlation Table of Histological Tau with Indicators of Inflammation and Neurodegenerative Markers.
CD45

Iba-1

MHCII

GFAP

Hippocampal

NeuN

Volume

Brain

PSD95

Weight

HT7

.537**

.265

.121***

.433*

-.282

-.152

-.374*

-.481**

AT8

.481**

.424

.361

.514**

-.453**

-.102

-2.63

-.640***

pSer396

.622***

.657***

.599**

.751***

-.724***

-.049

-.327

-.684***

Gallyas

.775***

.671***

.583**

.679***

-.847***

-.577**

-.388*

-.811***

Table 2. Pearson correlation table of four histological measurements of tau deposition indicate strong
relationships with markers of inflammation and neurodegeneration. Brain sections from mice ranging in age
from 50 to 610 days were stained as described in methods for NeuN, tau, and inflammatory measurements.
The average area occupied by positive staining was combined for anterior cortex, posterior cortex, and
hippocampus. Hippocampal volume was estimated using 8 sections through the entire region by the method
of Cavalieri. Brain weight was measured in mg. PSD-95 was measured in posterior cortical total
homogenates by immunoblot. Results were then normalized by calculating z-scores to facilitate comparison
with other markers over the lifespan. *p < 0.05. **p < 0.01. ***p < .001. Bolded text indicates the strongest
correlations for each histological tau marker.
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CHAPTER THREE:
THE IMPACT OF MOUSE AGE UPON THE SEVERITY OF TAU PATHOLOGY
AFTER VIRAL TAUP301L INTRACRANIAL INEJCTIONS
Introduction
Tauopathies define a cluster of diseases that are defined by the presence of pathological
tau, with the most common being Alzheimer’s disease (AD). Tau transgenic mouse models
express an abundant amount tauopathy from early in the life course (Ramsden et al., 2005). This
early expression, while helpful in animal models, may not translate well to the tauopathy found
in older adult humans. Many researchers have employed the use of adeno-associated viral
vectors (AAV) to produce tauopathy. This approach has been demonstrated to be a convenient
means of causing tauopathy (Cook et al., 2015; Jaworski et al., 2009; X. Liu et al., 2017;
Wegmann et al., 2019). Cook et al. (2015) compared the expression of viral tauP301L following
intracerebroventricular injections to the expression of the rTg4510 tau transgenic line. This study
found comparable tau expression and accumulation in both models, validating the model for
pathology. Furthermore, many different studies have used various AAV serotypes to model
tauopathy. Cearley and Wolfe (2006) compared several serotypes and found that AAV9 was the
serotype that had the largest dispersion of pathology to additional brain regions from the
injection site, including the contralateral side of the brain.
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Because the AAV model allows for initiation of a viral spread of pathology, this allows
researchers to examine the impact of age on pathology onset. This is an important advantage
because age is the greatest risk factor for an AD diagnosis and this viral model allows for the
examination of age, whereas, this is not feasible in transgenic models. Wegmann et al. (2019)
examined differences in tau expression using C57BL/6 mice aged between 3 and 22-24 months.
After a viral incubation period of 10 weeks, it was evident that the aged mice had more
tauopathy that spread to surrounding regions when compared to younger animals. Therefore,
demonstrating the ability to detect differences of age in viral models of tauopathy.
During aging, there is evidence that the body’s inflammatory state becomes primed to
respond to pro-inflammatory stimuli with a hyperactive release of cytokines and chemokines
(Franceschi & Campisi, 2014; Franceschi et al., 2007). While there is an increase in the immune
response of inflammation with age, these processes become less efficient with age (Licastro et
al., 2005). The system becomes less efficient at removing pathogens and pathology accumulation
and take significantly longer to recover from immune activation. Further analysis that have
examined the increased inflammatory status with age in relation to tau has demonstrated this
increased inflammatory status increases tau burden (Ghosh et al., 2013; Lee et al., 2010).
Because of this relationship, there is interest in further understanding if this aged innate immune
response accelerates tauopathy, and if so, which features of this response might be most
impactful and possibly amenable to intervention. Thus, this study used intracranial AAV9
tauP301L and AAV9 GFP in young, middle-aged, and old animals to establish a model to
investigate tauopathy based on the age of onset and how the aging immune response may impact
tauopathy in three aims.
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Aim One: To evaluate the effects of the injection (AAV9 GFP or AAV9 tauP301L) and
age (young, middle-aged, and old) on markers of tauopathy.
Aim one hypotheses: All tauP301L injected animals will have pathological tau
accumulation, but with the tauP301L injected oldest animals having the most severe pathology.
Aim Two: To evaluate the effects of the injection (AAV9 GFP or AAV9 tauP301L) and
age (young, middle-aged, and old) on markers of tau-related pathology such as immune
activation and neurodegeneration.
Aim two hypotheses: Because of the increase in immune activation with age, it is
hypothesized that there will be age-dependent increases in inflammation regardless of the
injection group. However, the immune response will be more exaggerated in the AAV9 tauP301L
injected animals. Furthermore, there will be more atrophy and neurodegeneration observed in the
tauP301L injected animals when compared to the GFP injected animals, but this will be most
severe in the oldest animals due to hypothesized increased tau burden.
Aim Three: In modeling tauopathy, it is important to have translational ability to induce
cognitive deficits. Therefore, to evaluate the effects of the injection (AAV9 GFP or AAV9
tauP301L) and age (young, middle-aged, and old), behavioral assessments were employed to
determine if there was the presence of any tau related cognitive impairments.
Aim three hypotheses: The AAV9 tauP301L injected animals will perform worse on
behavioral assessments. Because it is anticipated for the old tauP301L injected animals will have
the most pathology, it is also expected for these animals to perform the worst on behavioral
measures.
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Method
Animals and Experimental Design
Female (n=35) and male (n=34) C57BL/6 mice were ordered from the National Institute
of Aging. Animals were aged to 8, 12, 16 months of age and these roughly translate to young
adult, middle-aged, and older adulthood (Flurkey, Currer, & Harrison, 2007). Animals were kept
on a 12-hour light cycle and were provided food water ad libitum. Once animals were aged,
stereotaxic surgeries were conducted. Prior to injections, all animals were anesthetized with 3%
isoflurane (Henry Schein; Melville, NY, USF; Cat. No. 029404) and received 0.5mg/kg
buprenorphine SR (ZooPharm; Laramine, WY, USA) for post-operative analgesia. 2uL of viral
injections were administered to bilateral hippocampi (coordinates ML:+/-2.7, AP:-2.7, DV:-3.0)
and anterior region of the cortex (coordinates ML:+/-2.20, AP:2.2, DV:-3.0) relative to bregma
using a glass pulled pipette needle attached with heat shrink tubing to a 10μL Hamilton syringe
(Hamilton, Pompton Plains, NJ; cat. no. 80000) at a rate of 0.5μL/minute. Weights were
measured weekly to confirm the general health status of the mice post-surgery. At 3.5 months
post-surgery, behavioral assessments were conducted to determine if there was any evidence of
cognitive impairment. Two weeks after behavioral assessments, brain tissues were collected
(Figure 7 ).
Viral Production
Glycerol stock of competent SURE2 cells containing green fluorescent protein (GFP)
plasmid that included the woodchuck hepatitis virus post-transcriptional regulatory element
(WPRE) was graciously provided by Dr. Kevin Nash from the University of South Florida.
WPRE can enhance expression of viral cargo genes and elongate the period of viral expression
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(Loeb et al., 1999). The tauP301L cDNA was obtained from Genewiz (Genewiz, South Plainfield,
NJ, USA). The expression plasmids contained cytomegalovirus (CMV) enhancer with chicken β
actin (CBA) promoter. This allows for expression in the CNS with limited expression in motor
neurons (Gray et al., 2011). To construct the tauP301L plasmid, an additional GFP plasmid was
cloned, and enzyme restriction digests were conducted at the AgeI and SalI sites to remove the
GFP genetic sequence. Then ligation was performed to insert the tauP301L genetic sequence to the
GFP plasmid backbone containing WPRE. Both viruses were transfected with the AAV9
plasmid and XX6 helper plasmid in HEK293T cells. Viruses were collected and purified using
iodixanol gradients and ultracentrifugation. Viruses were then concentrated using Amicon ultra15 centrifugal filters (Sigma, Burlington, MA, USA; Cat. No. UFC910024) with DPBS (pH 7.4).
Ten μL aliquots of virus were stored at -80˚C until the day of injection to avoid multiple freeze
and thaw cycles. Viral titering was conducted using RT qPCR with primers targeted to the
WPRE sequence. Both viruses were diluted to 8.8+1011 vector genomes (vg)/uL. To ensure that
the intracranial injections were successful and estimate the original dispersion of the tau virus,
the AAV9 tauP301L injections also included 8.8+1010 vg/uL of AAV9 GFP.
Behavioral Assessments
All behavioral tests were conducted by an experimenter blind to injection and age groups
of all mice. Open field assessment was conducted to determine general activity and to acclimate
the animals to behavioral handling. Animals were placed in the open field (L 40mm/ W 40mm/H
40mm) enclosure from BioSeb (Vitrolles France) and tracked with AnyMaze software (Stoelting,
Wood Dale, IL, USA; cat. no. 60000) for 10-minute trials. The total distance traveled was
measured. Rotarod was used to evaluate the animal’s motor skill and to identify any potential
motor impairments. This test was conducted over two days with 4 trials on each day. Animals
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were placed on the TSE (TSE Systems, Chesterfield, MO, USA) rotarod apparatus, which is a
rotating rod that increases in speed through the duration of the 5-minute trial. There was at least
20 minutes between each trial to minimize muscle fatigue over trials. The latency to fall was
recorded for analysis.
To evaluate visuospatial navigation memory, the radial arm water maze (RAWM) was
conducted. A detailed protocol has been previously published along with the scoring sheets
(Alamed, Wilcock, Diamond, Gordon, & Morgan, 2006). This test was conducted over four days
in a 6-arm maze that radiates from the center that can be filled with water and external cues are
placed on the wall. For each animal, the goal arm of the 6-arm maze that houses the platform
remained the same, but the start arm was changed with each trial. Furthermore, the goal arm was
changed between animals to avoid any overt olfactory cues. Across all four days, each animal
underwent 15 trials for 1 minute each. On day one, mice were trained by alternating between a
visible and hidden platform. Furthermore, if the mouse failed to reach the platform on day one
after the 1-minute trial, the animal was guided to the platform. The number of incorrect arm
entries that included all four limbs to be in the arm were recorded as errors. Day two involves
only the hidden platform, again, incorrect arm entries were noted. Day three measured reversal
learning. This involved the hidden platform being switched to the arm that is 180˚ across the
maze from the original goal arm. Finally, on day four mice were tested for capability to see,
swim towards, and ascend the platform. The visible cues were removed from the wall and the
visible platform was placed in the center of the maze. No flag was used. The latency to reach the
visual platform was recorded. The number of errors and platform latency were averaged in sets
of three to create 5 blocks of trials for each day.
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Tissue Collection
Four months after the injection of the AAV viruses, tissues were collected in the same
manner as the previous study. The mice were anesthetized with 0.1mL/10g Somnasol (0.25mL in
10mL of H2O) and placed on a heating pad to maintain body heat to reduce any artefactual tau
phosphorylation caused by reduced body temperature during anesthesia (Planel et al., 2007).
Animals were perfused transcardially with 25mL of 0.9% normal saline solution. Once the
animals were perfused, the brains were immediately extracted. The brains were placed on an iced
stage and the right hemisphere was dissected into the anterior region of the cortex (ACX),
posterior region of the cortex (PCX), and the hippocampus (HPC) and brain regions were
immediately frozen on dry ice. Brain region specimens were stored at -80˚C until
homogenization for biochemical analysis. The left hemisphere was immediately immersed in
20mL of freshly prepared 4% paraformaldehyde (pH 7.4) for 24 hours at 4˚C. After 24 hours, the
left hemispheres were cryoprotected, where each brain was placed successively in 10, 20, and
30% sucrose for 24 hours. The brain hemispheres were stored at 4˚C until sectioned. Brains were
horizontally sectioned with a freezing microtome at a 25μm thickness and placed into
Dulbecco’s phosphate buffered saline with 10 mM sodium azide solution (7.4 pH) except for
every 10th section that was sectioned at 50μm thickness for hippocampal volumetric analysis.
Tissue Homogenization and Biochemical Analysis
The HPC was added to 10v/w to RIPA (50mM Tris-Cl, 150nM NaCl,1% NP40, 0.1%
SDS, 0.05% sodium deoxycholate) buffer with protease inhibitor cocktail (Sigma Aldrich, St.
Louis, MO, USA; Cat. No. P8340), deacetylase inhibitor cocktail (MedChem Express,
Monmouth Junction, NJ, USA; Cat. No. HY-K0030) phenylmethanesulfonyl fluoride (Sigma
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Aldrich, St. Louis, MO, USA; Cat. No. P7626), and phosphate inhibitor cocktails II and III
(Sigma Aldrich, St. Louis, MO, USA; Cat. Nos. P5726 & P0044, respectively).
Samples were then homogenized first by a rotating mechanical pestle and then by
sonication. Once sonicated, a consistent aliquot was removed from each sample and then
centrifuged at 50,000g for 1 hour at 4˚C. The remaining crude homogenate was stored at -80 ˚C
until analysis. Once the centrifugation was complete, the supernatant was removed and stored as
the detergent soluble fraction, and the detergent insoluble pellet was kept for formic acid
processing. Formic acid processing was conducted by adding a fifth of the total sample volume
of 70% formic acid to each pellet and homogenized by a rotating mechanical pestle. After the
pellets were homogenized, the samples were gently rotated for 30 minutes. 15.1M NaOH was
added to neutralize formic acid samples. Once neutralized, 1M Tris-Base (pH 7.6) was added to
a 1:2 ratio to the homogenate volume. Individual insoluble samples were adjusted to pH of 7.
Protein concentrations for crude, supernatant, and formic acid fractions were determined by
Pierce BCA protein assays.
Samples for both the detergent soluble and insoluble fractions were used for all tau
ELISA assays. The assays were used to detect total tau ( Fisher Scientific, Cat. No. KHB0041),
phosphorylated Ser199-tau (Fisher Scientific, Cat. No. KHB7041), and phosphorylated Ser396tau (Fisher Scientific, Cat. No. KHB7031). All samples were first diluted (1:100) in RIPA, then
diluted appropriately for each ELISA assay in the provided ELISA kit’s buffer. All
concentrations derived from the ELISA assay were normalized to the sample’s total protein
concentration.
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Histopathology
Tissues from both AAV9 GFP and AAV9 tauP301L groups were placed in free-floating
multi-sample staining trays for each marker. The trays were placed in an endogenous peroxidase
blocking solution (10% methanol, 3%H2O2 in PBS). The tissues were washed 3 times with PBS
and then placed in permeabilizing solution (0.2% lysine, 1%Trition X100, 4% normal goat serum
in PBS). Tissues were then incubated overnight in the appropriate antibody (Table 3). The
following morning, tissues were washed with PBS and incubated for 2 hours in the
corresponding biotinylated secondary antibody. This step was excluded if the primary antibody
was biotinylated. After the two-hour incubation period, tissues were washed with PBS and
placed in Vectastain® Elite® ABC kit solution (Vector Laboratories, Burlingame, CA; cat. no.
PK-6100) to enhance the enzyme complex. Again, tissues were washed with PBS for 2 washes
and TBS for a final wash. Following the TBS wash, tissues were placed in a color development
solution (0.05% DAB, 0.5% Ni2+, .03% H2O2,) for 5 minutes. To stop color development,
tissues were washed with TBS for one wash and then 2 PBS washes. Upon the completion of
staining, tissues were mounted on microscope slides (Fisher Scientific, Waltham, MA; cat. no.
1255015), dehydrated, and cover slipped with DPX mounting medium (Electron Microscopy
Sciences, Hatfield, PA; cat. no. 13512).
For Gallyas and cresyl violet staining, tissue sections were first mounted on microscope
slides and dried overnight. Gallyas staining is a silver stain that identifies NFTs (Uchihara,
2007). On the day of Gallyas staining, sections were briefly rehydrated and then placed in a
pretreatment solution (5% periodic acid). After a series of washes, the slides were immersed in a
silver enhancing solution (10% potassium iodide, 4%NaOH, 0.035% silver nitrate) for one
minute before incubating for 10 minutes in a 0.5% acetic acid solution. Slides were then placed
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in a working developer solution (2.5% sodium carbonate, 0.1% ammonium nitrate, 0.1% silver
nitrate, 0.5% tungstosilic acid, 0.2% formaldehyde) for approximately 10 minutes. Upon
development, slides were washed with 0.5% acetic acid followed by water washes. Then slides
were immersed in a gold toning solution (0.1% gold chloride solution) followed by an additional
water wash. Then slides were incubated in a solution to remove traces of unconjugated silver
salts (0.1% sodium thiosulphate solution) and a final water wash. Slides were immediately
dehydrated and coverslipped.
The cresyl violet stain was conducted on pre-mounted 50μm tissues. The, slides were
briefly rehydrated and then placed in a 0.05% cresyl violet dye solution. After staining, slides
were briefly placed in an acetic acid water solution (pH 3.5) and rinsed in water. Slides were
then dehydrated and coverslipped in DPX (Electronic Microscopy Sciences Cat. No. 13512).
Once the DPX was dried, slides were scanned using ZEISS Axio Scan.Z1. Scanned slides were
analyzed using NearCyte tissue analysis IAE software (created by Andrew Lesniak). The entire
tissues section was identified and immunopositive pixels above a user-defined threshold were
measured. The threshold parameters were derived using several sections with light and dark
staining and held constant throughout the analysis. The fraction of the total region occupied by
immunopositive pixels was calculated. Cresyl violet staining was conducted to measure
hippocampal volume using the method of Cavalieri.
Statistical Analysis
All statistical analyses were conducted using IBM SPSS Statistics 25 (Armonk, New
York, USA) and figures were created with GraphPad Prism 8 (La Jolla, CA). For aim one of this
study to address any group differences on markers of tauopathy from histological staining and
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ELISA assay concentrations based on injection (GFP vs tauP301L) or age (young, middle-aged,
and old), two-way ANOVAs were conducted. To address aim two, to determine if there were any
group differences based on injection (GFP vs tauP301L) or age (young, middle-aged, and old) for
histological markers of tau-related pathology of inflammation and neurodegeneration, two-way
ANOVAs were also conducted. For aim three, to assess any evidence of group differences based
on injection (GFP vs tauP301L) or age (young, middle-aged) in the behavioral assessment, a twoway ANOVA or two-way repeated measures ANOVAs were conducted. For the first behavioral
task, the open field examined the total distance traveled in a ten-minute trial, so a two-way
ANOVA was conducted. However, the rotarod and RAWM are tasks that have multiple trials;
therefore, two-way repeated measures ANOVAs were conducted. To assess motor function, the
rotarod was used to measure the time each mouse spent on a rotating rod during eight fiveminute trails over the course of two consecutive days. A two-way repeated measures ANOVA
was conducted to identify any group differences based on injection (GFP vs tauP301L) or age
(young, middle-aged, and old). Finally, for each day of the RAWM, repeated measures two-way
ANOVAs were conducted to determine any group differences based on injection (GFP vs
tauP301L) or age (young, middle-aged, and old) on the average of errors for five blocks of trials
for day one, day two, and the reversal task. For the open pool task, time to reach the platform
was analyzed by a two-way repeated measures ANOVA to determine any group differences
based on injection (GFP vs tauP301L) or age (young, middle-aged, and old). All significant
ANOVAs were followed by Fisher’s least significance difference (LSD) post-hoc analyses to
identify the groups that were significantly different.
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Results
Aim One: Effects of Age Differences on Tauopathy
GFP and total tau expression
The overarching goal of this study was to examine if the age of animal at the onset of a
viral method of inducing tauopathy could impact the severity of pathology. To first determine
that the intracranial injections were successful, immunostaining for GFP and total tau expression
were conducted. Histological GFP and tau representative images can be seen in Figure 8. For
most injections in the hippocampus, the GFP immunoreactivity filled most of the structure in
both the GFP group and in the P301L tau groups, that also included a 1/10th dose of the GFP
virus in addition to the tau virus. The GFP staining area was measured using image analysis and
a two-way ANOVA was conducted to determine group differences based on age and injection
for histological GFP. There was a main effect of injection group, F (1,58) = 495.21, p < .001,
where the GFP injected animals had significantly more GFP staining when compared to the
tauP301L injected animals (Figure 9A). The age groups did not have any significant differences in
GFP staining (p = .478). As expected, when examining histological total tau measured by HT7,
there was no detectable staining in mice injected with the GFP virus, resulting in a significant
main effect of injection, (F (1,58) = 194.43, p < .001; Figure 9B). Also, HT7 staining did not
vary significantly when age groups were examined (p = .599). After measuring total tau
concentration by ELISA assays using both the detergent soluble and detergent insoluble
fractions, two-way ANOVAs were conducted. There were main effects of the viral injection
group for both detergent soluble, (F(1,58) = 135.42, p < .001, Figure 9C) and detergent insoluble
(F(1,55) = 52.46, p < .001, Figure 9D) fractions, where there was evidence of total tau in the
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tauP301L injected animals and no total tau in the GFP injected animals. Similar to histological total
tau, both soluble (p = .393) and insoluble (p = .753) total tau did not change statistically
significantly with age. There were three animals that did not have enough insoluble sample to
run in the ELISA assays that included one young tauP301L injected, middle-aged tauP301L injected,
and one old GFP injected mouse. These three animals were not included for any of the detergent
insoluble analyses.
Phospho-tau epitopes
To further evaluate tauopathy, phospho-tau isoforms were measured both histologically
(Figure 8) and by ELISA assays (Figure 10). Two-way ANOVAs were conducted to determine
the effect of injection group and age at onset of pathology to determine group differences for
indicators of phosphorylated tau. Histological phospho-tau Ser202/Thr205, measured by AT8,
not only had main effects of both injection group (F(2,57) = 93.17, p < .001) and age (F(2, 57) =
3.61, p = .033), but the interaction of age and injection (F(2,57) = 3.42, p = .040) was significant
(Figure 10A). There was no AT8 staining in the GFP injected animals. For the tauP301L injected
animals, Fisher’s LSD post-hoc analysis indicated that the old animals (M = .050, SEM = .004)
displayed significantly more AT8 staining when compared to the young animals (M = .025, SEM
= .005; p = .032). After measuring the concentration of phospho-tau Ser199 (pSer199) in the
detergent soluble and detergent insoluble fractions, two-way ANOVAs were conducted to
determine differences between injection group and age. For both the detergent soluble (F(1,58) =
78.33, p < .001) and detergent insoluble pSer199-tau (F(1,55) = 38.92, p < .001) there were main
effects of injection group, where the tauP301L injected animals demonstrated the presence of
pSer199 and the GFP inject animals did not (Figure 10B-C). However, both fractions failed to
have any significant effects of age (p > .514).
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To examine group differences based on injection and age group on indicators of latestage tau phosphorylation, two-way ANOVAs were conducted for indicators of phospho-tau
Ser396 (pSer396). Histological pSer396-tau had a main effect of injection group (F(1,58) =
68.273, p < .001), but did not have any main effect of age (Figure 10D). The tauP301L injected
animals had evidence of pSer396 staining, but GFP injected animals did not. When examining
the soluble fraction pSer396-tau concentration, there was also a main effect of injection (F(1,58)
= 39.719, p < .001) where the tauP301L injected animals demonstrated pSer396-tau compared to
no pSer396 detected in the GFP injected animals (Figure 10E). There was no evidence of an age
effect (p = .890). Consistent with the soluble pSer396, the insoluble fraction had a main effect of
injection, (F(1,55) = 27.07, p < .001), but failed to detect a main effect for age (p = .418; Figure
10F). Still, although not statistically significant, there was a trend for both the histological
measure of pSer396-tau and ELISA measured insoluble pSer396-tau to increase in older mice.
Neurofibrillary tangles
To further estimated the severity of tauopathy silver staining of tau fibrils (NFTs) using
the Gallyas method was conducted and analyzed by two-way ANOVA. Main effects of injection
(F(1, 58) = 87.03, p < .001 and age (F(2,58) = 6.66, p = .002) were significant. The tauP301L
injected animals had evidence of Gallyas staining whereas, there was no evidence of staining in
the GFP injected mice. In addition, there was evidence of an age-dependent increase in Gallyas
staining for the tauP301L injected animals, evidenced by a significant interaction of age and
injection (F(2,58) = 7.29, p = .001; Figure 11). Fisher’s LSD post-hoc analysis confirmed that
the old mice had significantly more Gallyas staining when compared to young (p = .004) or
middle-age (p = .015) mice.
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Aim Two: Effects of Injection and Age on Immune Activation and
Neurodegeneration
Microglia
In the aging process there is a general increase of immune activation that includes
markers of microglial activation. The current study posited that the aging immune system could
impact the of rate tauopathy. A two-way ANOVA was conducted to determine if there were
group differences of injection and age on microglia measured by Iba-1. There was no significant
difference based on injection group (F(1,58) = 1.06, p = .307) or age (F(2,58) = 0.63, p = .534)
for Iba-1 (Figure12A). In addition, microglia activation can induce MHCII expression, so
staining by MHCII was conducted (Figure 12B). There were significant effects for injection
(F(1,58) = 13.76, p < .001) and age (F(2,58) = 4.76, p = .012). These results indicate that there
was more MHCII expression in the tauP301L injected mice(M = 0.041, SEM = 0.004) when
compared to the GFP injected mice (M = 0.022, SEM = 0.004; Figure 12B). Fisher’s LSD posthoc analysis determined the young animals (M = 0.020, SEM = .005) had significantly less
MHCII expression when compared to middle aged animals (M = 0.036, SEM = .005; p = .027)
and old animals (M = 0.039, SEM = 0.004; p = .006).
Neurodegeneration
A neuronal stain, NeuN, was used to determine if there was any effect of injection or age
on neurons. A two-way ANOVA failed to find a significant effect of injection group (F(1,58) =
2.18, p = .146; Figure 13A). There was also no significant effect of age (F(2,58) = 1.20, p =
.380), although there was a trend for less NeuN staining in the oldest mice injected with tau
virus. In addition, hippocampal volume was assessed by Nissl staining and using the method of
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Cavalieri to estimate the volume. A two-way ANOVA indicated there was a significant reduction
of hippocampal volume in the tauP301L injected animals when compared to the GFP injected
animals, (F(1,58) = 18.178, p < .001, See Figure 13B), but there was no significant effect of age
(p = .558).
Aim Three: Effects of Injection and Age on Cognitive Measures
Open field
The first behavioral measure was the open field to assess general activity. The total
distance traveled over a 10-minute trial was measured and a two-way ANOVA was conducted to
identify group differences of injection and age. Results found a significant main effect of age
(F(2,58) = 5.46, p = .007; Figure 14). Fisher’s LSD post-hoc analysis found that old animals (M
= 29.67, SEM = 2.943), irrespective of injection group, traveled significantly less distance when
compared to young (M = 40.70, SEM = 3.377; p = .016) and middle-aged animals (M = 43.17,
SEM = 2.943; p = .004).
Rotarod
Mice were tested for locomotor activity by their capacity to remain on an accelerating
rotating rod. A two-way repeated measures ANOVA was conducted combining the two days of
testing for the rotarod (Figure 15). Results were consistent with the open field, where there was a
significant effect of age (F(2,58) = 13.74, p < .001), but not injection group. Fisher’s LSD posthoc identified an age-dependent effect where the young animals spent the most time on the
rotarod when compared to middle-age (p = .049) and old (p < .001) animals (Figure 15B and C).
Additionally, the middle-age animals spent significantly more time on the rotarod when
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compared to old (p = .003) animals. Within-subjects tests indicate (F(5.67, 328.57) = 25.66, p <
.001) that all groups improved on the task over the two days of testing.
Radial arm water maze
To examine any translational effect of cognitive impairment, repeated measures two-way
ANOVAs were conducted on the radial arm water maze tasks to determine any effects of
injection group or age (see Figure 16). On day one, the training day, there was no significant
effect of injection (F(1,33) = 0.024, p = .879) or age (F(2,33) = 0.225), p = .8800). On day two
of the RAWM, or the testing day, there was a significant main effect of age (F(2, 33) = 7.38, p =
.002) and a significant interaction of age and injection group (F(2,33) = 3.61, p = .038). Fisher’s
LSD post-hoc analysis indicated that older mice made significantly more errors when compared
to young (p = .001) and middle-aged (p = .021) mice. However, when examining the interaction
of age and injection, the old GFP injected animals (M = 4.17, SEM = .527) performed more
errors on the second day of the RAWM when compared to young (M = 1.16, SEM = .416)
middle-aged (M = 1.83, SEM = .445) GFP injected animals, whereas for the tauP301L injected
animals, the three age groups performed similarly with no age differences (Figure 17).
To assess the capacity to learn a new platform location, the location of the hidden
platform arm was reversed on the third day of RAWM testing. A two-way repeated measures
ANOVA did not find any significant differences based on injection group (F(1,33) = 1.96, p =
.170) or age (F(2,33) = .544, p = .585) (Figure 18A). To ensure that the animals were able to
reach and ascend the platform without visual impairment, the open pool task with a visible
platform was conducted. If any animal was unable to complete the task in 20 seconds or less on
the final trial, the animal was excluded from all RAWM tasks due to potential visual impairment
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(Figure 18B). A two-way repeated measures ANOVA revealed no group differences on the
animals that were able to reach the platform within 20 seconds based on injection (F(1,33) =
0.200, p = .658) or age (F(2,33) = 0.022, p = .978).
There were 5 animals that died prior to behavioral assessments. Deaths were attributed to
old age or other inexplicable causes. However, it should be noted that there were 22 additional
animals excluded from RAWM analyses. Of these 22 animals, 12 animals were not able to swim
over the four days of testing in the water maze, 6 had visible eye problems, and 4 had seizures on
days of testing. The oldest animals were the ones most afflicted by health concerns (50%) and
inability to swim (83.3%). Three animals had to be excluded from all RAWM tasks due to not
reaching the visible platform within 20 seconds on the last trial of the open pool task. The final
sample sizes in each group were young GFP n = 8, middle-aged GFP n = 7, old GFP n = 5,
young tau n = 10, middle-aged tau n = 5, and old tau n = 4 for the radial arm water maze
analyses.
Discussion
The goal of this study was to examine the effects of age on the viral onset of a model of
tauopathy. There were three specific aims that this study was designed to address. The first aim
was to examine injection and age differences on markers of tauopathy. Total tau and GFP
immunostaining indicated that the intracranial injections were successful. Tau was only
expressed in mice receiving viral administration of tauP301L. GFP was expressed at higher levels
in AAV9 GFP injected mice and filled the target area well. Because AAV9 GFP was included in
the AAV9 tauP301L injectate, tau injected mice also expressed GFP, but in lower levels than the
AAV9 GFP injected mice. Furthermore, when age differences were examined, there were no
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differences in viral expression with age, thus indicating there was no effect of age on the GFP’s
or tauP301L’s abilities to transduce neurons.
When examining markers of tauopathy, the AAV9 tauP301L virus was able to induce
pathological changes in tau similar to other viral models of tauP301L(Jaworski et al., 2009; Klein
et al., 2004; You et al., 2019). There was evidence of an age effect in the AAV9 tauP301L for
histological early phosphorylated tau and NFTs, where older animals had significantly more
pathology than the younger aged animals. The present study was able to validate the ability of
AAV9 tauP301L to produce a hallmark indicator of AD-related pathology, Gallyas positive NFTs.
In addition, the detergent insoluble fraction of brain homogenate samples had evidence of late
phosphorylated tau (pSer396-tau) where there was a trend that the older animals had a greater
concentration when compared to younger groups. However, there is a large amount of variation
for the insoluble pSer396 and could be due to possible inter-animal variation where not every
animal produces pathology at the same rate. This becomes more evident in the insoluble
homogenate fractions and soluble and histological late phosphorylated tau. This variation could
be impacted by several factors including variation in the seeding ability of tau to propagate
pathology.
The second aim of this study was to examine injection and age differences on markers of
immune activation and neurodegeneration. There was a clear effect of aging for MHCII staining
where the young animals had significantly less expression when compared to middle-aged and
old animals, where this was more exaggerated in the tauP301L injected animals, providing
evidence of this model to exhibit the increase in inflammation in the aging process. Our findings
of age differences for reactive immune function, is consistent with work conducted by Cook et
al. (2015) that have observed significant age effects of reactive immune function in a viral model
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of tauP301L. However, there were no significant difference in the present study for microglia as
measured by Iba-1. It is important to note that Iba-1 is a pan microglia marker, and it does not
reflect only activated microglia. Additional testing of reactive inflammation should be examined
for further investigation of the immune response including markers of reactive microglia such as
CD11b, and CD45.
The tauP301L injected animals had a reduction in hippocampal volume; however, this was
not impacted by age. With the observed age-dependent increase in Gallyas positive NFTs, there
was an anticipation for the old tauP301L mice to have more atrophy when compared to the young
and middle-aged tauP301L injected groups. Yet the amounts of atrophy were similar at all ages for
tauP301L mice. Further investigations will be aimed at understanding potential causes for this. One
avenue that warrants investigation is to determine if there is a difference in the content of tau
oligomers. Tau oligomers are small hyperphosphorylated tau aggregates that some researchers
suggest to be one of the most toxic forms of tau (Shafiei, Guerrero-Muñoz, & Castillo-Carranza,
2017). This toxic species occurs early in the progression of pathology; therefore, it would be
advantageous to examine this factor in relation to hippocampal volume (Lasagna‐Reeves et al.,
2012; Maeda et al., 2006). In addition, when examining a neuronal marker, there were no
significant differences, yet, it is important to note that the old tauP301L injected animals appeared
to have a reduction in neuronal staining when compared to the young and middle-aged tauP301L
injected animals although it failed to reach significance.
The third and final aim of this study was to address age differences in GFP and tauP301L
injected groups on measures of motor function and visuospatial memory. The behavioral
assessment indicated a significant effect of age on motor function. This effect was demonstrated
on each of the tasks as the aged mice performed worse on each of the measures the open field
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and rotarod. Furthermore, the aged animals were much more likely to be excluded due to an
inability to swim in the memory task. The traditional criterion of successful learning in the
RAWM is less than one error on the last block of trials on day two. The only groups that were
able to successfully achieve this goal were the young and middle-aged GFP injected mice.
In conclusion, the AAV9 tauP301L virus was able to induce a model of tauopathy that
exhibits an effect of age. This model included markers of tauopathy, inflammation,
neurodegeneration, and behavioral deficits. The effects of age were demonstrated on early
histological phospho-tau, NFTs, and activated inflammation. The behavioral measures
demonstrated effects of age, where animals regardless of injection group, demonstrated worse
motor performance. The visuospatial task demonstrated impairment in the each of tauP301L
injected groups, and the old GFP group. While further investigation is warranted to understand
the age differences in detail, this preliminary work has provided the necessary validation for
continuing the use of this model. With further evidence of this model to demonstrate a viral
model of tauopathy that can be influenced by the aging immune system, could produce a
translationally meaningful representation of clinical cases. Not only would this produce a
representative animal model, but it has the potential to aid in the identification of immune
pathways that might be amendable to clinical intervention to reduce tau burden in the future.
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Figure 7. Experimental design and flowchart with sample sizes for the examination of mouse age upon the severity of tau
P301L
pathology after viral tau
intracranial injections. Red boxes indicate attrition due to mortality, health concerns, or inability
to swim.
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Table 3.
Summary of Primary and Secondary Antibodies Used for
Immunohistochemistry
Primary
Antibodies

Host

Target

Source

Dilution

HT7

Mouse

Total Tau

Invitrogen
MN1000B

1:5k

AT8

Mouse

Phosphorylated tau at
Serine 202 and threonine
205 epitopes

Invitrogen
MN1020B

1:10k

pSer396

Rabbit

Phosphorylated tau at the
Serine 396 epitope

Anaspec
AS 54977-025

I-A/I-E

Rat

Major histocompatibility
complex II

BD Pharmingen
556999

1:5k

Iba1

Rabbit

Microglia

Fuji
019-19741

1:5k

NeuN

Mouse

Neurons

Millipore
MAB377b

1:30k

Secondary
Antibodies

Host

Target

Manufacturer

Dilution

Goat

Conjugates to Rabbit host
primary antibodies

Goat

Conjugates to Rat host
primary antibodies

Goat

Conjugates to Chicken host
primary antibodies

Biotinylated
Anti-Rabbit
IgG
Biotinylated
Anti-Rat
IgG
Biotinylated
AntiChicken IgY
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Vector
Laboratories
BA-1000
Vector
Laboratories
BA-9400
Vector
Laboratories
BA-9010

1:30k

1:3k

1:3k

1:3k

Figure 8. Micrograph representation of the hippocampal area for
histological GFP and tau staining. A-D, GFP staining; E-H, total tau
measured by HT7; I-L phosphorylated tau at ser202/thr205 (AT8); M-P,
phosphorylated tau at ser396 (pSer396); Q-T, Gallyas staining. 16-monthP301L
old GFP injected mouse A,E, I, M,Q; B,F,J,N,R tau
injected 12-monthP301L
old mouse; C,G,K,O,Stau
injected 16-month-old mouse; D,H,L,P,T
P301L
tau
injected 20-month-old mouse. Scale bar 500μm.
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Figure 9. Expression of GFP and tau after intracranial injections of AAV9 GFP and
P301L

AAV9 tau
in young, middle-aged, and old mice. (A) Quantification of the
histological positive fractional area for GFP staining, n = 64. (B) Quantification of
histological positive fractional area for total tau (HT7) staining, n = 64 (C) The
hippocampus was dissected, homogenized, and the detergent soluble fraction was
isolated, and total tau ELISA assays were used to quantify soluble total tau
concentration that is displayed normalized to the total protein values, n = 64. (D)
The hippocampal detergent insoluble fraction was isolated and used total tau ELISA
assays to quantify viral expression normalized to the total protein values, n = 61.
Data are presented as mean ±SEM (error bars). Each dot represents one mouse. ***p
< .001.
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P301L

Figure 10. Age-dependent increases in early histological phospho-tau pSer202/pThr 205 in AAV9 tau
but not in
late histological phospho-tau pSer396. ( A) quantification of the histological positive fractional area of phospho-tau
P301L
pSer202/pThr205 (AT8) demonstrating an age-dependent increase in the tau
injected animals, n = 63. (B) The
pSer199 concentration measured by ELISA assays on the detergent soluble hippocampal fraction normalized to total
protein, n = 64. (C) The pSer199 concentration measured by ELISA assays on the detergent insoluble hippocampal
fraction normalized to total protein, n = 61. (D) Quantification of the histological positive fractional area of
phospho-tau Ser396, n = 64. (E) The pSer396 concentration measured by ELISA assays on the detergent soluble
hippocampal fraction normalized to total protein, n = 64. (F) The pSer396 concentration measured by ELISA assays
on the detergent insoluble hippocampal fraction normalized to total protein, n = 61. Data are presented as mean
±SEM (error bars). Each dot represents one mouse. *** p < .001 * p < .05.
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Figure 11 Age-dependent increase in Gallyas staining in
P301L
the tau
injected mice. Quantification of the
histological positive fractional area for Gallyas staining
by injection and age groups, n = 64. Data are presented
as mean ±SEM (error bars). Each dot represents one
mouse. *** p < .001. * p < .05 Fisher’s LSD post-hoc
analysis.
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Figure 12. Quantification of histological immune markers by age and injection. (A) Quantification of histological
positive fractional area ratio of pan microglia by Iba1 staining, n = 64. (B) Quantification of histological positive
area ratio of MHCII expression microglia by MHCII staining, n = 64. Data are presented as mean ±SEM (error
bars). Each dot represents one mouse *** p < .001. ** p < .01 and * p < .05 Fisher’s LSD post-hoc analysis.
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P301L

Figure 13. The AAV9 tau
injected mice experienced a reduction in hippocampal volume, but no significant
reduction in neurons. (A) Quantification of histological positive fractional area of neurons, measured by NeuN
staining, n = 64. (B) Quantification of hippocampal volume estimated using 8 sections through the entire
P301L
region by the method of Cavalieri indicated that the tau
mice had a reduction of hippocampal volume
compared to the AAV9 GFP injected mice; , n = 64. Data are presented as mean ±SEM (error bars). Each dot
represents one mouse. *** denotes p < .001 main effects of injection from a two-way ANOVA.
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Figure 14. The old animals, regardless of injection
group, traveled significantly less distance when
compared to middle-aged and young animals, n = 64.
Data are presented as mean ±SEM (error bars). Each dot
represents one mouse. ** p < .01 * p < .05.
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P301L

Figure 15. Older mice for both AAV9 GFP and AAV9 tau
injection groups spent significantly less time on
the rotarod when compared to the middle-aged and young mice. (A), Two-day rotarod performance for young,
P301L
middle-aged, and old mice for both AAV9 GFP and AAV9 tau
injected mice demonstrate an effect of age
where older animals perform worse when compared to young and middle-aged mice. B, Two-day rotarod
performance for young, middle-aged, and old AAV9 GFP injected mice demonstrate an age dependent
decrease in performance where the increasing age groups performed significantly worse, n = 32. C, Two-day
P301L
rotarod performance for young, middle-aged, and old AAV9 tau
injected mice demonstrate the old mice
spent significantly less time on the rotarod when compared to young and middle-aged animals, n = 32. Data
are presented as mean ±SEM (error bars). *** p< .001, * p < .05. Fisher’s post-hoc analysis.
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Figure 16. Mice did not vary by injection or age group for the average number of errors on day one of the radial arm
water maze. (A) The five blocks of trials for day one of the radial arm water maze for all injection and age groups, n =
39. (B) The five blocks of trials for young, middle-aged, and old AAV9 GFP injected mice on day one of the radial arm
P301L
water maze, n = 20. (C) The five blocks of trials for young, middle-aged, and old AAV9 tau
injected mice on day
one of the radial arm water maze, n = 19. Data are presented as mean ±SEM (error bars). RAWM = radial arm water
maze.
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P301L

Figure 17. Old animals that received AAV9 GFP and AAV9 tau
injections performed more errors on day two of
testing for the radial arm water maze when compared to the young animals. (A) The five blocks of trials for all injection
and age groups on day two of the radial arm water maze, n = 39. (B) The five blocks of trials for young, middle-aged, and
old AAV9 GFP injected mice on day one of the radial arm water maze. Old animals made significantly more errors when
compared to young and middle-aged animals, n = 20(C). The five blocks of trials for young, middle-aged, and old AAV9
P301L
tau
injected mice on day two of the radial arm water maze, n = 19. Data are presented as mean ±SEM (error bars).
RAWM = radial arm water * p < .05 Fisher’s LSD post-hoc analysis.
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Figure 18. No difference between age or injection groups for radial arm water maze reversal task or time to
reach the platform on the open pool. (A) The number of errors made on the reversal task of the radial arm
water maze for all injection and age groups, n = 39. (B) Time to reach the platform in the open pool task to
ensure animals are free of visual impairments for all injection and age groups, n = 39. RAWM = radial arm
water maze.
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CHAPTER FOUR:
COMPARISON OF THREE DIFFERENT TAU VIRAL ISOFORMS
Introduction
Tau has proven to be a critical feature of AD-related pathology. It is a defining disease
hallmark that is strongly related to cognitive dysfunction and neurodegeneration (Abbott et al.,
2006; Bejanin et al., 2017; Gordon et al., 2018; Hanseeuw et al., 2019; Malpas et al., 2020). This
has caused many researchers to focus their efforts to further understanding this protein.
Currently, there is no known mutation for the tau MAPT gene that is exclusive to AD. This
causes an issue for researchers as animal models are not able to directly translate the inherent tau
AD-related pathology. However, other mutations related to tau have been identified and allowed
for the generation of tau transgenic animal models that allow researchers to understand key
biological mechanisms that occur in the progression of tauopathy. Tauopathies all include
pathological tau; however, the most striking differences are the brain regions that are afflicted.
The different brain regions and cell-types that are afflicted by tau burden are responsible for the
clinical manifestations of the disease. For instance, AD-related tauopathy begins in the
transentorhinal cortex and hippocampal regions that are associated with memory, whereas,
frontotemporal dementia begins in areas of the frontal cortex related to reasoning (H. Braak &
Braak, 1995; Rosen et al., 2002). Other tauopathies are associated with aberrant tau
accumulation in other brain regions (corticobasal syndrome) and even glial expression
(progressive supranuclear palsy). These tau aggregates appear unique because transfer of tau
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aggregates associated with different diseases was maintained upon serial transfer into mice
(Narasimhan et al., 2017).
AAV modeling allows researchers to specify the location of pathology (Daya & Berns,
2008). Specifically, the use of AAV serotype 9 efficiently transduces neurons within the central
nervous system and when using tau constructs has proven to promote tauopathy in the central
nervous system (Cearley & Wolfe, 2006; Cook et al., 2015). Because early AD-related tauopathy
is apparent in the entorhinal cortex and hippocampus, AAV9 allows viral integrations to start in
these critical regions. Therefore, while tau mutations are not yet identified with AD, the use of
AAV9 methodology to promote tauopathy in critical AD-related areas, allows for a new models
of tauopathy that might be more translational for AD. Researchers have employed AAV9 to
introduce wild-type and mutated tau to induce models of tauopathy.
Wild-type tau refers to tau that lacks any mutation. These models include inducing a
larger amount of tau in the brain. Because wild-type tau does not aggregate as avidly as mutant
tau variants, the rate of pathology and the severity is decreased when compared to mutated tau
models (Hasegawa, Smith, & Goedert, 1998; Nacharaju et al., 1999). A commonly used tau
mutation in viral models is P301L. The P301L mutation refers to the substitution of proline for a
leucine amino acid at the 301st residue (using the 2N4R sequence) in exon 10 located in the
microtubule binding domain. This mutation has commonly been used for modeling tauopathy
including the JNPL3 and rTg4510 transgenic mice (Lewis et al., 2000; Santacruz et al., 2005).
These animal models exhibit extensive tau burden, inflammatory response, neurodegeneration,
and deficits in cognitive function. This mutation has long been associated with increases in toxic
tau forms and reduced microtubule binding (Barghorn et al., 2000; Bunker, Kamath, Wilson,
Jordan, & Feinstein, 2006; Chang, Kim, Yin, Nagaraja, & Kuret, 2008).
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Clinical manifestations of the P301L mutation in fronto-temporal lobe dementia include a
younger mean age of symptom onset (45-64 years of age) when compared to other mutations and
a disease duration between 4 and 16 years. Clinical symptoms include disinhibition including
aggressive behavior, restlessness, word finding difficulties, and egocentrism (Heutink et al.,
1997; Reed et al., 1997; Van Swieten et al., 1999). In a clinical study that examined three
families known to have this mutation, individuals showed evidence of neuronal loss and cortical
atrophy coupled with evidence of inflammation (Heutink et al., 1997; Van Swieten et al., 1999).
R406W is a mutation that is the result of an arginine amino acid being replaced by
tryptophan and is located on exon 13 outside of the microtubule binding domain. While this
mutation has not been used for viral applications, the mutation has been used in cell work, and to
lesser extent transgenic lines. However, in clinical settings, this mutation has been associated
with a later age of onset (54.2-64.2 years of age) and exhibits less toxicity that allows for a
longer duration of disease (up to 20 years) (Van Swieten et al., 1999). Reed et al. (1997)
conducted a brain autopsy from an individual with a long family histology of the R406W
mutation. Out of four generations, there were 27 individuals and approximately 56% were
affected by the mutation. Electron microscopy evidenced paired helical filaments (PHFs) in the
midbrain regions, neurofibrillary tangles (NFTs), and ghost tangles in the hippocampal region,
and cortical atrophy. The family’s clinical symptomology included memory loss, personality
change, and mild parkinsonism.
Because there are several mutations of tau that are related to tauopathies, it is important
to compare how these mutations model tauopathy. Therefore, the purpose of this study was to
use AAV9 methodology to compare 2N4R wild-type tau, tauP301L, and tauR406W to examine which
model may give the most translational applications for AD models in three aims.
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Aim One: To investigate whether the amount of tauopathy is affected by tau variants.
Aim one hypotheses: TauP301L is shown to have an earlier onset and more severe
progression when compared to tauR406W in clinical cases. Furthermore, in animal work tauP301L
has more disease pathology when compared to tauwild-type. Because of the increased pathology
severity, it is hypothesized that the tauP301L will produce more tauopathy compared to the other
forms of tau.
Aim Two: To compare other markers of tau-related pathology such as immune activation
and neurodegeneration to determine which virus produces a robust model of tauopathy.
Aim two hypotheses: Given tauP301L is more prone to aggregation, it would be expected
that this would be coupled with an increased immune response and have more of indicators of
neurodegeneration, such as a reduction in hippocampal volume, and neuronal density.
Aim Three: To evaluate the if the tau variants can induce cognitive impairments
Aim three hypothesis: Because tauP301L is more prone to aggregation, in addition to more
tau burden and tau-related pathology, it is anticipated that the tauP301L will perform worse on
measures of memory.
Method
Animals and Experimental Design
Female (n=20) and male (n=20) C57BL/6 mice were ordered from the National Institute
of Aging. Animals were kept on a 12-hour light cycle and were provided food water ad libitum.
All animals were aged to 12 months and received intracranial stereotaxic surgeries to bilateral
hippocampi (coordinates ML:+/-2.7, AP:-2.7, DV:-3.0) and anterior region of the cortex
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(coordinates ML:+/-2.20, AP:2.2, DV:-3.0) relative to bregma using a glass pulled pipette needle
attached with heat shrink tubing to a 10μL Hamilton syringe (Hamilton, Pompton Plains, NJ; cat.
no. 80000) at a rate of 0.5μL/minute. Following the surgery, animals were placed on heating
pads and observed during recovery. Weights were measured weekly to confirm health status of
mice during the duration following the surgeries until tissue collection. At 3.5 months of viral
incubation, behavioral assessments were conducted to observe any deficits in memory. Brain
tissue was collected two weeks following behavioral assessments. (Figure 19 )
Viral Constructs
Glycerol stocks of competent SURE2 cells containing 2N4R tauwild-type and GFP plasmids
were donated by Dr. Kevin Nash from the University of South Florida. The gene fragments for
both 2N4R tauP301L and 2N4R tauR406W were ordered from GeneWiz (Genewiz, South Plainfield,
NJ, USA). However, only the GFP plasmid contained the woodchuck hepatitis virus
posttranscriptional regulatory element (WPRE) an important element that can enhance
expression of viral cargo genes and elongate the period of viral expression (Loeb et al., 1999).
To ensure the plasmids were consistent and included WPRE, three additional GFP plasmids were
prepared and restriction digests were conducted at the AgeI and SalI sites to remove the GFP
fragments. Ligations were conducted to insert each of the tau plasmids (P301L, R406W, and
wild-type). To ensure expression in the CNS each expression plasmid contained cytomegalovirus
(CMV) enhancer with the chicken β actin (CBA) promoter (Gray et al., 2011). The plasmids
were transfected with AAV9 plasmid and XX6 helper plasmid in HEK293T cells. Viruses were
purified using iodixanol gradients and ultracentrifugation. Further steps were conducted to
concentrate the virus with Amicon ultra-15 centrifugal filters (Sigma, Burlington, MA, USA;
Cat. No. UFC910024) with DPBS (pH 7.4). Ten μL aliquots were made and stored in the -80˚C
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until the day of surgery to eliminate freeze thaw cycles. RT qPCR were used for viral titering
with primers for the WPRE sequence. Each virus was diluted to 8.8+1011 vector genomes
(vg)/uL. Furthermore, 8.8+1010vg/mL of AAV9 GFP was added to each of the tau viruses so the
area of injection could be monitored with GFP staining.
Behavioral Assessments
All behavioral tests were conducted by an experimenter blind to tau variant injection
group of the mice. Open field assessment was conducted to determine general activity and to
acclimate the animals to behavioral handling. Animals were placed in the open field (L 40mm/
W 40mm/H 40mm) enclosure from BioSeb (Vitrolles France) and tracked with AnyMaze
software (Stoelting, Wood Dale, IL, USA; cat. no. 60000) for 10-minute trials. The total distance
traveled was measured. Rotarod was used to evaluate the animal’s motor skill and to identify any
potential motor impairments. This test was conducted over two days with 4 trials on each day.
Animals were placed on the TSE (TSE Systems, Chesterfield, MO, USA) rotarod apparatus,
which is a rotating rod that increases in speed through the duration of the 5-minute trial. There
was at least 20 minutes between each trial to minimize muscle fatigue over trials. The latency to
fall was recorded for analysis.
To evaluate visuospatial navigation memory the radial arm water maze (RAWM) was
conducted as described previously (Alamed et al., 2006). This test was conducted over four days
and utilized a 6-arm maze that radiates from the center that was filled with water and external
cues that were placed on the wall. For each animal, the goal arm of the 6-arm maze that houses
the platform remained the same, but the start arm changed with each trial. Furthermore, the goal
arm was changed between animals to avoid any overt olfactory cues. Across all four days, each
animal underwent 15 trials for 1 minute each. On day one, mice were trained by alternating
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between a visible and hidden platform. Furthermore, if the mouse failed to reach the platform on
day one after the 1-minute trial, the animal was guided to the platform. The number of incorrect
arm entries that included all four limbs to be in the arm were recorded as errors. Day two
involves only the hidden platform, again, incorrect arm entries were noted. Day three measured
reversal learning. The hidden platform was moved to the arm 180˚ across the maze from the
original goal arm. Finally; on day four, mice were tested for capability to see, swim towards, and
ascend the visual platform. The visible cues were removed from the wall and the visible platform
was placed in the center of the maze. No flag was used. The latency to reach the visual platform
was recorded. The number of errors and platform latencies were averaged in sets of three to
create 5 blocks of trials each day.
Tissue Collection
Four months after the injection of the AAV, tissues were collected in an identical manner
as the previous studies. The mice were anesthetized with 0.1mL/10g Somnasol (0.25mL in 10mL
of H2O) and placed on a heating pad to maintain body heat to reduce any artefactual tau
phosphorylation caused by reduced body temperature during anesthesia (Planel et al., 2007).
Animals were perfused transcardially with 25mL of 0.9% normal saline solution. Once the
animals were perfused, the brains were immediately extracted. The brains were placed on an iced
stage and the right hemisphere was dissected into the anterior region of the cortex (ACX),
posterior region of the cortex (PCX), and the hippocampus (HPC) and brain regions were
immediately frozen on dry ice. Brain region specimens were stored at -80˚C until
homogenization for biochemical analysis. The left hemisphere was immediately immersed in
20mL of freshly prepared 4% paraformaldehyde (pH 7.4) for 24 hours at 4˚C. After 24 hours, the
left hemispheres were cryoprotected, where each brain was placed successively in 10, 20, and
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30% sucrose for 24 hours. The brain hemispheres were stored at 4˚C until sectioned. Brains were
horizontally sectioned with a freezing microtome at a 25μm thickness and placed into
Dulbecco’s phosphate buffered saline with 10 mM sodium azide solution (7.4 pH) except for
every 10th section that was sectioned at 50μm thickness for hippocampal volumetric analysis.
Tissue Homogenization and Biochemical Analysis
The HPC was added 10v/w to RIPA buffer (50mM Tris-Cl, 150nM NaCl,1% NP40,
0.1% SDS, 0.05% sodium deoxycholate) buffer containing protease inhibitor cocktail (Sigma
Aldrich, St. Louis, MO, USA; Cat. No. P8340), deacetylase inhibitor cocktail (MedChem
Express, Monmouth Junction, NJ, USA; Cat. No. HY-K0030) phenylmethanesulfonyl fluoride
(Sigma Aldrich, St. Louis, MO, USA; Cat. No. P7626), and phosphate inhibitor cocktails II and
III (Sigma Aldrich, St. Louis, MO, USA; Cat. Nos. P5726 & P0044, respectively).
Homogenization was conducted by first using a mechanical pestle and then by sonication. An
aliquot of the crude homogenate was centrifuged at 50,000g at 4˚C for 1 hour. The supernatant
was removed and stored at -80˚C as the detergent soluble fraction. The detergent insoluble pellet
was treated with 70% formic acid. Once treated with formic acid, the pellet was then
homogenized with the mechanical pestle. After the pellets were homogenized, the samples were
gently rotated for 30 minutes. 1M Tris-Base (pH 7.6) was added to each sample and then
neutralized with 15.1M NaOH. Individual samples were adjusted to pH of 7. Pierce BCA protein
assays were done to determine the protein concentration of both the detergent soluble and
insoluble fractions.
Samples for both the detergent soluble and insoluble fractions were used for all tau
ELISA assays. Assays were used to detect total tau ( Fisher Scientific, Cat. No. KHB0041),
phosphorylated Ser199-tau (Fisher Scientific, Cat. No. KHB7041), and phosphorylated Ser39680

tau (Fisher Scientific, Cat. No. KHB7031). All samples were first diluted (1:100) in RIPA, then
diluted appropriately for each ELISA assay in the provided ELISA kit’s buffer. All
concentrations derived from the ELISA assay were normalized to the sample’s total protein
concentration.
Histopathology
Six to eight sections from each mouse were placed in free-floating multi-sample staining
trays for each marker. The trays were placed in an endogenous peroxidase blocking solution
(10% methanol, 3%H2O2 in PBS). The tissues were washed 3 times with PBS and then placed in
permeabilizing solution (0.2% lysine, 1%Trition X100, 4% normal goat serum in PBS). Tissues
were then incubated overnight in the appropriate antibody (see Table 3). The following morning,
tissues were washed with PBS and incubated for 2 hours in the corresponding biotinylated
secondary antibody. This step was excluded if the primary antibody was biotinylated. After the
two-hour incubation period, tissues were washed with PBS and placed in Vectastain® Elite®
ABC kit solution (Vector Laboratories, Burlingame, CA; cat. no. PK-6100) to enhance the
enzyme complex. Again, tissues were washed with PBS for 2 washes and the final wash was in
TBS. Following the TBS wash, tissues were placed in a color development solution (0.05%
DAB, 0.5% Ni2+, .03% H2O2) for 5 minutes. To stop color development, tissues were washed
with TBS for one wash and then 2 PBS washes. Upon the completion of staining, tissues were
mounted on microscope slides (Fisher Scientific, Waltham, MA; cat. no. 1255015), dehydrated,
and cover slipped with DPX mounting medium (Electron Microscopy Sciences, Hatfield, PA;
cat. no. 13512).
For Gallyas and cresyl violet staining, tissue sections were first mounted on microscope
slides and dried overnight. Gallyas staining is a silver stain that identifies NFTs (Uchihara,
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2007). On the day of Gallyas staining, sections were briefly rehydrated and then placed in a
pretreatment solution (5% periodic acid). After a series of washes, the slides were immersed in a
silver enhancing solution (10% potassium iodide, 4%NaOH, 0.035% silver nitrate) for one
minute before incubating for 10 minutes in a 0.5% acetic acid solution. Slides were then placed
in a working developer solution (2.5% sodium carbonate, 0.1% ammonium nitrate, 0.1% silver
nitrate, 0.5% tungstosilic acid, 0.2% formaldehyde) for approximately 10 minutes. Upon
development, slides were washed with 0.5% acetic acid followed by water washes. Then slides
were immersed in a gold toning solution (0.1% gold chloride solution) followed by an additional
water wash. Then slides were incubated in a solution to remove traces of unconjugated silver
salts (0.1% sodium thiosulphate solution) and a final water wash. Slides were immediately
dehydrated and coverslipped.
The cresyl violet stain was conducted on pre-mounted 50μm tissues. The day of the stain,
slides were briefly rehydrated and then place in a 0.05% cresyl violet dye solution. After
staining, slides were briefly placed in an acetic acid water solution (pH 3.5) and rinsed in water.
Slides were then dehydrated and coverslipped in DPX (Electronic Microscopy Sciences Cat. No.
13512). Once the DPX was dried, slides were scanned using ZEISS Axio Scan.Z1. Scanned
slides were analyzed using NearCyte tissue analysis IAE software (created by Andrew Lesniak).
The entire tissue sections were identified and immunopositive pixels above a user-defined
threshold were measured. The threshold parameters were derived using several sections with
light and dark staining and held constant throughout the remaining analysis. The fraction of the
total region occupied by immunopositive pixels was calculated. Cresyl violet staining was
conducted to measure hippocampal volume using the method of Cavalieri.
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Statistical Analysis
All statistical analyses were conducted using IBM SPSS Statistics 25 (Armonk, New
York, USA) and figures were created with GraphPad Prism 8 (La Jolla, CA). For aim one, oneway ANOVAs were conducted to determine the group differences based on injection group
(GFP, tauP301L, tauR40w, and tauwild-type) for markers of tauopathy from histological staining and
ELISA assays concentrations. In addition, one-way ANOVAs were also used to identify any
group differences based on injection group (GFP, tauP301L, tauR406w, and tauwild-type) for tau-related
pathology including histological markers of inflammation and neurodegeneration were
conducted for aim two. Furthermore, to assess any group differences on measures of the
behavioral assessments for aim three, both a one-way ANOVA, and one-way repeated measures
ANOVAs were conducted. First the open field was analyzed by one-way ANOVA for any group
differences based on injection group (GFP, tauP301L, tauR40w, and tauwild-type) for the total distance
traveled during a 10-minute trial. Because the rotarod task is conducted in eight trials over two
consecutive days, a repeated measures one-way ANOVA was conducted to determine any group
differences based on injection group (GFP, tauP301L, tauR40w, and tauwild-type) for the time to the
animal was able to remain on a rotating rod over the two days of testing. Finally, the RAWM has
five blocks of trials on each day of the tasks and to identify any groups differences based on
injection group (GFP, tauP301L, tauR40w, and tauwild-type) for task performance by the average of
error made, one-way repeated measures ANOVAs were conducted for day one, day two, and the
reversal task. For the open pool task, time to reach the platform was analyzed by a one-way
repeated measures ANOVA to determine any group differences based on injection group (GFP,
tauP301L, tauR40w, and tauwild-type) to reach the platform through all five blocks of trials. All

83

significant ANOVAs were followed by Fisher’s least significance difference (LSD) post-hoc
analyses to identify the significantly different groups.
Results
Aim One: Effect of tau variants on tauopathy
GFP and total tau expression
The goal of this study was to compare three different tau viruses to determine which virus
will produce a more translational model of AD tauopathy. To define the brain area affected by
the intracranial injections, each tau virus included a 1/10th titer of GFP relative to the GFP
injected mice. Representative images for both GFP and total tau staining can be seen in Figure
20. Histological GFP was examined by one-way ANOVA to determine if there were significant
differences between GFP, tauP301L, tauR406W, and tauwild-type injected animals. There were
significant differences found, F(3,35) = 130.538, p < .001 (Figure 21A) and Fisher’s LSD posthoc analysis determined that GFP injected mice had significantly greater GFP staining compared
to tauP301L (p < .001), tauR406W (p < .001), and tauwild-type (p < .001). In addition, tauR406W had
significantly more GFP staining compared to tauP301L (p < .001) and tauwild-type (p < .001). To
measure histological total tau, HT7 was used for staining. A one-way ANOVA found significant
differences between GFP and the tau viruses (F(3,35) = 73.580, p <.001; tauP301L (p < .001),
tauR406W (p < .001), and tauwild-type (p < .001), Figure 21B). Out of the tau virus groups, tauwild-type
had the greatest amount of HT7 staining and was significantly more when compared to tauP301L
(p < .001) and tauR406W (p < .001) (Figure 20E-H). Total tau concentrations were detected by
ELISA assays for both the detergent soluble and detergent insoluble fractions. For soluble
fraction total tau, a one-way ANOVA detected significant group differences (F(3,35) = 27.556, p
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< .001; Figure 21C). Fisher’s LSD post-hoc analysis found significant differences between GFP
and two of the tau viruses, tauP301L (p < .001) and tauwild-type (p < .001). Additional differences
were detected between tauP301L and tauR406W (p < .001) where there was significantly less total
soluble tau in the tauR406W(p < .001) injected animals. In fact, there was no significant difference
between tauR406W and GFP (p = .150). Because of the low tauR406W concentration, there was also
a significant difference between tauR406W and tauwild-type (p < .001). The detergent insoluble
fraction total tau concentration had similar group differences as the soluble fraction (F(3,33) =
19.531, p < .001; Figure 21D). There were significant differences between GFP and two of the
tau viruses, tauP301L (p < .001) and tauwild-type (p = .019). Furthermore, the tauP301L had a
significantly greater concentration when compared to the other tau viruses tauR406W (p < .001)
and tauwild-type (p < .001). There were two animals that did not have enough insoluble sample to
run in the ELISA assays that included one tauP301L injected, and one tauwild-type injected mouse.
These two animals were not included for any of the detergent insoluble analyses.
Phospho-tau epitopes
To further examine markers of tauopathy, markers of early and late phosphorylation
epitopes were examined (Figure 22). Histological AT8 was used as an early marker of
phosphorylation and significant group differences were observed (F(3,35) = 29.652, p < .001).
Fisher’s LSD post-hoc analysis revealed significant differences between tauwild-type and all other
viruses (ps < .001), as tauwild-type had the greatest amount of AT8 staining. In addition, there were
significant differences between GFP and tauR406W (p = .007), but the difference between GFP and
tauP301L failed to reach significance (p = .201). When examining phospho-tau Ser199 (pSer199)
concentration in the detergent soluble fraction, a one-way ANOVA revealed significant
differences (F(3,35) = 27.556, p < .001) between tau variants. It was evident that there were
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significant concentrations of tauP301L and tauwild-type. Tauwild-type had the greatest detergent soluble
pSer199 concentration and was significantly different from tauP301L (p = .010), tauR406W (p <
.001), and GFP (p < .001) injection groups. Furthermore, tauP301L was significantly different
from tauR406W (p = .001) and GFP (p < .001). While there was a low concentration of tauR406W
detected, it was not significantly different from the GFP (p = .184) injected animals. Similar to
the soluble fraction, pSer199 concentration in the insoluble fraction was significantly elevated in
tauP301L and tauwild-type injected mice. However, for the insoluble fraction, tauP301L had the highest
pSer199 concentration and was significantly different from GFP (p < .001), tauR406w (p <
.001), and tauwild-type (p = .032) groups. Additionally, tauwild-type had significantly greater
concentrations of insoluble pSer199 when compared to GFP (p = .014) and tauR406W (p = .027).
Consistent with the soluble fraction, tauR406W was not significantly different from the GFP (p =
.818) injected groups.
Phospho-tau Ser396 (pSer396) was examined as an indicator of late phosphorylation.
Histological pSer396 had a significant main effect of tau variant, F(3,35) = 8.753, p < .001
(Figure 20M-P). Tauwild-type had the greatest amount of staining and was significantly different
from GFP (p < .001), tauP301L (p = .033), and tauR406W (p < .001) injection groups. Furthermore,
tauP301L had significantly more pSer396 staining compared to GFP (p = .017). There was a low
amount of pSer396 staining in the tauR406W injected animals, but this was not significantly
different from the GFP (p = .501) injected animals. The detergent soluble pSer396 concentration
was comparable to histological pSer396 (F(3,35) = 22.166, p < .001), where tauwild-type had the
greatest concentration and was significantly greater than all other viruses (ps < .001).
Furthermore, tauP301L had the second highest concentration and was significantly different from
GFP (p = .003) and tauR406W (p = .008). The tauR406W failed to have a significant difference from
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the GFP injected animals (p = .804). While the pSer396 concentration of the insoluble fraction
had significant differences (F(3,33) = 12.787, p < .001), tauP301L had the highest concentration
was the significantly greater than all other groups (ps < .001).
Neurofibrillary tangles
Gallyas staining was used to examine if there was a significant difference in silver
positive NFTs based on the tau variant injection group. A one-way ANOVA was conducted and
revealed significant differences among the groups (F(3,35) = 23.132, p < .001; Figure 23). Only
tauP301L (p < .001) and tauwild-type (p = .028) had Gallyas staining that was significantly different
from the GFP injected animals. Furthermore, tauP301L had the greatest amount of Gallyas staining
when compared to the tauwild-type (p < .001) injected animals.
Aim Two: Effects of tau variant on other markers of tau-related pathology
Microglia
Iba1 staining was used to monitor microglia in each injection group. A one-way ANOVA
was conducted (Figure 24A). There were no significant differences based on the injection group
(F(3, 35) = 2.067, p = .122). However, when examining microglial activation using MHCII
marker, there were significant group differences (F(3,35) = 14.478, p < .001; see Figure 24B).
Tauwild-type had the greatest amount of MHCII staining when compared to all other injection
groups (ps < .003). The only other significant difference was observed for tauR406W and GFP
injection groups, where tauR406W had significantly greater MHCII staining when compared to the
GFP (p = .006) injection group.
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Neurodegeneration
When examining the histological neuronal marker, NeuN, there was a significant
injection group difference (F(3,35) = 6.840, p = .004; Figure 25A). Fisher’s LSD found that GFP
and tauP301L had significantly less neuronal staining when compared to tauR406W (ps < .003) and
tauwild-type (ps < .04). Furthermore, there was a main effect of injection group on hippocampal
volume, (F(3,35) = 5.668, p = .003), and tauwild-type had a significant reduction in hippocampal
volume when compared to all other viruses (p < .0095; Figure 25B).
Aim Three: Effect of tau variant on activity, locomotor, and cognitive performance
Open field and rotarod
The first behavioral measure that was assessed was the open field as an indicator of
general activity. The total distance traveled over a 10-minute trial was determined by a one-way
ANOVA. There were no significant differences observed between the tau variants, F(3,33) =
.122, p = .946 (Figure 26). Two tauR406W injected animals were excluded from the open filed
assessment because of a technical issue with the software. Similarly, rotarod performance had no
significant difference between the tau variants (F(3,35) = .928, p = .437; Figure 27).
Radial arm water maze
To evaluate any evidence of cognitive impairment based on injection group differences,
the RAWM task was performed and analyzed by repeated measures two-way ANOVAs for each
day of testing. For day one, the training day, there was no evidence of differences based on the
injection group, F(3,23) = .796, p = .508 (Figure 28A). However, on the testing day, or day two,
there was a main effect of tau variant injection group (F(3,23) = 7.716, p = .001; Figure 28B).
Fisher’s LSD post-hoc analysis determined that the tauP301L performed significantly more errors
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when compared to the GFP (p = .025) and the tauR406W (p = .003) injection groups. In addition,
the tauwild-type also performed significantly more errors when compared to GFP (p = .004) and
tauR406W(p < .001) but was not significantly different from the tauP301L (p = .571) group. When
working memory, as demonstrated by the reversal task of the RAWM, was examined for any
evidence of injection differences, there was no significant main effect of tau variant injection
group on the amount of errors (F(3,23) = 1.572, p = .223; Figure 29A).
All animals were evaluated for indication of visual impairment by the open pool task. If
any animal took longer than 20 seconds to find the visual platform on the last trial, the animal
was believed to have a visual impairment and the animal was excluded from any RAWM
analysis. For the animals that were able to complete the task in 20 seconds or less, a repeated
measures ANOVA was conducted to determine if there were any differences based on injection
group (Figure 29B). Fisher’s LSD post-hoc analysis indicated that the only group that performed
significantly different, was the tauwild-type injection group (ps < .002), where this group required
significantly more time to reach the visible platform than the other three groups.
There was one animal that died prior to the behavioral assessments. An additional 9
animals were excluded from RAWM analysis. Of the 9 animals, 2 had eye problems, 2 were not
able to swim, and 5 were noted to have seizures on the days of testing. In addition, three animals
were excluded due to not being able to reach the visible platform in 20 seconds on the last trial of
the open pool task. This resulted in final sample sizes of GFP n = 7, tauP301L n = 5, tauR406W n =
9, and tauwild-type n = 6 for the radial arm water maze.
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Discussion
This study aimed to understand the difference in the capacity of three tau genetic variants
that included tauP301L, tauR406W, and full length tauwild-type, for their ability to produce a
translational model of AD tauopathy. There were three aims that this study was designed to
address. Aim one was to determine if there were differences in tauopathy based on the injection
group. It was evident that tauP301L and tauwild-type viruses were able to produce models of
tauopathy. While both injection groups were able to induce tauopathy, the two groups did so in
different ways. The tauP301L virus had the highest concentrations of early and late phosphorylated
tau in the detergent insoluble fractions. Furthermore, the tauP301L also had the most abundance of
NFT staining measured by Gallyas staining. These findings resonate with the enhanced
aggregation propensity for tauP301L relative to tauwild-type. In comparison, the tauwild-type injection
group had significantly greater total tau staining coupled with higher concentrations of early and
late phosphorylated tau in the detergent soluble fractions.
While tauP301L and tauwild-type viruses demonstrated models of tauopathy, the tauR406W
injection group failed to demonstrate a sufficient model of tauopathy. The expression of soluble
total tau and histological total tau demonstrated that the intracranial injections were successful;
however, this group only had evidence of early phosphorylated tau in the histological probe, and
overall expression appeared reduced. Research has demonstrated that this mutation has a less
severe progression of pathology (Van Swieten et al., 1999). Intriguingly, this injection group also
had the greatest amount of GFP staining among the tau viruses. However, with the greater
amount of GFP staining, one possibility is there is less competition between the GFP and
tauR406W viruses for cellular resources than for the other tau variants.
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Studies that have examined the in vitro differences of 2N4R mutant and wild-type tau in
their ability to aggregate and polymerize (Mutreja, Combs, & Gamblin, 2018). TauP301L exhibited
a greater degree of aggregation polymerization when compared to tauwild-type and tauR406W groups.
In addition, tauP301L proved to have the most reduction in microtubule assembly and stabilization
when compared to tauR406W and tauwild-type. Electron micrographs demonstrated that while tauP301L
had a lower number of filaments, tauP301L had the longest filaments in comparison to both
tauR406W and tauwild-type. These findings specific to the P301L mutation are consistent with the
increased amount of Gallyas staining and concentrations of insoluble tau found in the tauP301L
injection group observed in the current study.
Aim two was to examine injection group differences on markers of tauopathy-related
pathology. When examining markers of immune function, there were no group differences on
total microglia staining, but there was evidence of group differences for activated inflammation
by MHCII staining. Tauwild-type had the greatest amount of MHCII activation that was coupled
with the greatest amount of hippocampal atrophy. All of the tau viral groups had a reduction in
hippocampal volume, but it was the most striking in the tauwild-type injection group, nearing a
mean difference of 50% compared with GFP injected mice. When examining a neuronal marker,
the results were unexpected. The GFP and tauP301L injected groups had the least amount of NeuN
staining while the tauwild-type and then tauR406W had the greatest amount of neuronal staining. As
the tauR406W injected group displayed the least amount of pathology of the tau injection groups, it
is expected that this group would have a high level of neuronal staining. This suggests that
changes in volume are larger than changes in neuron number. Changes in volume could reflect
loss of fibers, synapses and/or glial components. If the neuron number is not reduced but the
hippocampal volume is reduced, then those neurons would be present in a smaller volume
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leading to the observed effects. Thus, tauwild-type and tauR406W might express more synapse/fiber
toxicity, while tauP301L and GFP are more toxic to neurons.
When examining the findings of aim three to identify potential behavioral impairments, it
was apparent that there were no significant differences in motor function across the injected
groups as demonstrated by the open field and the rotarod tests. However, group differences based
on the injection groups were observed on the RAWM. On the testing day, both the tauP301L and
tauwild-type injected mice performed significantly worse on the memory task when compared to the
GFP and the tauR406W injected groups. When open pool was examined for the animal’s ability to
reach the visible platform among animals without visual impairment, the tauwild-type injection
group took longer to reach the platform. This increased latency to reach the platform may
indicate that it took longer for these animals to orient themselves to the center of the maze. It is
important to note that the two groups that experienced cognitive impairments, also had the
greatest number of animals excluded from analysis.
The overall evidence of this study shows that both tauP301L and tauwild-type viruses were
sufficiently able to induce models of tauopathy that are consistent with the literature (Cook et al.,
2015; Jaworski et al., 2009). However as previously discussed, there are different mechanisms
that are accumulating in that pathology, where both mechanisms can be translated to behavioral
measures. This area warrants further examination. One hypothesis is that the tauwild-type injection
could be inducing oligomeric tau whereas the tauP301L injection produces NFTs. Tau oligomers
have been found to be a toxic form of tau that occurs early in the progression of pathology
(Lasagna‐Reeves et al., 2012; Maeda et al., 2006; Shafiei et al., 2017). Work by Maeda, Sato,
and Takashima (2018) observed significant differences in the structure of in vitro oligomers that
are formed in respect to tauwild-type, tauP301L, and tauR406W. The most remarkable difference was
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observed for the tauP301L where the oligomers were smaller in diameter. Furthermore, they found
a significantly greater numbers of granules for the mutated forms of tau. This study provides
evidence that there are inherent differences that should be expected for each of the tau viruses
regarding oligomers.
In respect to lack of pathology in the tauR406W injection group, research has shown that
this mutation causes pathology to progress at a slower rate specifically when compared to the
tauP301L mutation (Van Swieten et al., 1999). This evidence demonstrates tauR406W as an
ineffective model of tauopathy due to the lack of significant differences between the GFP
injected group, and limited evidence for early phosphorylated tau.
Overall, the most surprising observation is that the wild type tau caused the greatest
toxicity in terms of tissue atrophy. One criticisms of the existing transgenic mouse models of
tauopathy is that they are not models of AD, but most appropriately models of frontotemporal
lobe dementia, the disorder caused by these mutations. The results of the present study, using
older mice than most such analyses, suggests that AAV9 tauwild type might be used to study tau
pathology that is more closely related to that found in AD than in frontotemporal lobe dementia.
The evidence that comparing different viral tau isoforms in middle-age, demonstrates the
importance of incorporating age in animal models of AD, Incorporating age has the potential to
increase the modeling’s translational relevancy to clinical cases as it is an age-related disease.
Furthermore, the comparison of various models of tauopathy to determine a more relevant AD
model is important as the field has not identified an AD specific model tauopathy as observed in
clinical cases. As there is no method of the intervention for the disease, it is important to identify
more translationally meaningful models to identify potential areas for future interventions or
preventative approaches that may be more advantageous.
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In conclusion this study provided evidence that both tauP301L and tauwild-type viruses
created two different models of tauopathy that included similar translational behavioral deficits.
TauP301L produced an abundant amount of tauopathy that is less degradable in the insoluble forms
of tau and NFTs. Tauwild-type produced more soluble forms of tauopathy but a striking amount of
atrophy. These differences should be further investigated to determine the cause of these
differences to further determine the AD tauopathy translation ability of these models.
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P301L

Figure 19. Experimental design and flowchart with sample sizes for the comparison of intracranial viral GFP, tau
,
R406W
wild-type
tau
, and tau
injections. Red boxes indicate attrition due to mortality, health concerns, or inability to swim.
GFP= green florescent protein (control virus).
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Table 4.
Summary of Primary and Secondary Antibodies Used for
Immunohistochemistry
Primary
Antibodies

Host

Target

Source

Dilution

HT7

Mouse

Total Tau

Invitrogen
MN1000B

1:5k

AT8

Mouse

Phosphorylated tau at Serine
202 and threonine 205
epitopes

Invitrogen
MN1020B

1:10k

pSer396

Rabbit

Phosphorylated tau at the
Serine 396 epitope

Anaspec
AS 54977-025

I-A/I-E

Rat

Major histocompatibility
complex II

BD Pharmingen
556999

1:5k

Iba1

Rabbit

Microglia

Fuji
019-19741

1:5k

NeuN

Mouse

Neurons

Millipore
MAB377b

1:30k

Secondary
Antibodies

Host

Target

Manufacturer

Dilution

Biotinylated
Anti-Rabbit IgG

Goat

Conjugates to Rabbit host
primary antibodies

Biotinylated
Anti-Rat IgG

Goat

Conjugates to Rat host
primary antibodies

Biotinylated
Anti-Chicken
IgY

Goat

Conjugates to Chicken host
primary antibodies
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Vector
Laboratories
BA-1000
Vector
Laboratories
BA-9400
Vector
Laboratories
BA-9010

1:30k

1:3k

1:3k

1:3k

Figure 20. Micrograph representation of the hippocampal area for
histological GFP and tau staining. A-D, GFP staining; E-H, total tau
measured by HT7; I-L phosphorylated tau at ser202/thr205 (AT8);
M-P, phosphorylated tau at ser396 (pSer396); Q-T, Gallyas staining.
P301L
GFP injected mouse A,E, I, M,Q; B,F,J,N,R tau
injected mouse;
R406W
wild-type
C,G,K,O,S tau
mouse; D,H,L,P,T tau
. Scale bar 500μm.
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Figure 21. Scatterplots of individual animal’s expression of GFP and tau after
P301L
R406W
intracranial injections of AAV9 GFP, AAV9 tau
, AAV9 tau
, and AAV9
wild-type
tau
. (A) Quantification of histological positive fractional area for GFP
staining; n = 39. (B) Quantification of positive fractional area for histological
total tau (HT7); n = 39. (C) The hippocampus was dissected, homogenized, and
the detergent soluble fraction was isolated, and total tau ELISA assays to
quantify total tau (HT7) concentration normalized to the total protein values ; n
= 39. (D) The hippocampal detergent insoluble fraction was isolated and used
total tau ELISA assays to quantify total tau (HT7) concentration normalized to
the total protein values; n = 37. Data are presented as mean ±SEM (error bars).
Each dot represents one mouse. *** p < .001* p < .05 Fisher’s LSD post-hoc
analysis.
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P301L

wild-type

Figure 22. AAV9 tau
and tau
exhibit early and late phosphorylated indicators of tauopathy. (A). Quantification of
the positive fractional area of histological phospho-tau pSer202/pThr205 (AT8) demonstrating an age-dependent increase in
P301L
the tau
injected animals; n = 39. (B) The pSer199 concentration measured by ELISA assays on the detergent soluble
hippocampal fraction normalized to total protein; n = 39. (C) The pSer199 concentration measured by ELISA assays on the
detergent insoluble hippocampal fraction normalized to total protein; n = 37. (D) Quantification of the positive fractional
area of histological phospho-tau pSer396; n = 39. (E) The pSer396 concentration measured by ELISA assays on the
detergent soluble hippocampal fraction normalized to total protein; n = 39. (F) The pSer396 concentration measured by
ELISA assays on the detergent insoluble hippocampal fraction normalized to total protein; n = 37. Data are presented as
mean ±SEM (error bars). Each dot represents one mouse. *** p < .001 ** p < .01 * p < .05 Fisher’s LSD.
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P301L

wild-type

Figure 23. AAV9 tau
and AAV9 tau
produce
Gallyas silver positive neurofibrillary tau tangles.
Quantification of the positive fractional area for
Gallyas staining by injection and age groups; n = 39.
Data are presented as mean ±SEM (error bars). Each
dot represents one mouse. *** p < .001 and * p < .05
Fisher’s LSD post-hoc analysis.
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wild-type

Figure 24. AAV9 tau
had the greatest immune response measured by MHCII. Quantification of
histological immune markers by age and injection. (A) Quantification of positive area ratio of pan histological
microglia by Iba1 staining; n = 39. (B) Quantification of positive area ratio of histological MHCII expression
microglia by MHCII staining; n = 39. Data are presented as mean ±SEM (error bars). Each dot represents one
mouse. *** p < .001* p < .05 Fisher’s LSD post-hoc analysis.
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R406W

wild-type

wild-type

Figure 25. AAV9 Tau
and Tau
have greater neuronal density but AAV 9 tau
had significant
atrophy at the injection sites. (A) Quantification of the positive fractional area for NeuN staining for
injection groups; n = 39. (B) Quantification of hippocampal volume estimated using 8 sections through the
wild-type
entire region by the method of Cavalieri indicated that the tau
mice had a significant reduction of
hippocampal volume compared to the other injections; n = 39. Data are presented as mean ±SEM (error
bars). Each dot represents one mouse.*** p < .001,** p < .01,* p < .05 Fisher’s LSD post-hoc analysis.
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Figure 26. There was no difference in the distance
traveled for the open field based on AAV9 injection type;
n= 37. Data are presented as mean ±SEM (error bars).
Each dot represents one mouse.
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Figure 27. No difference in the time spent on the rotarod by AAV9
injection group over the two days of testing; n= 39. Data are presented as
mean ±SEM (error bars). Each dot represents one mouse.
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P301L

wild-type

Figure 28. AAV9 tau
and AAV9 tau
performed worse on the second day of the radial arm water maze when
R406W
compared to AAV9 tau
and AAV9 GFP. (A) The five blocks of trials for day one of the radial arm water maze
demonstrate no significant differences; n = 27. (B) The five blocks of trials for day one of the radial arm water maze
P301L
wild-type
R406W
demonstrated AAV9 tau
and AAV9 tau
injected mice performing more errors than AAV9 tau
and AAV9
GFP injected mice; n = 27. Data are presented as mean ±SEM (error bars). Each dot represents one mouse.* p < .05
Fisher’s LSD. RAWM = radial arm water maze.
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wild-type

Figure 29. There were no significant group differences on the radial arm water maze reversal task, but AAV9 tau
took a significant longer time to reach the platform in the open pool task. (A). The number of errors made on the reversal
task of the radial arm water maze for all injection groups, n = 27. (B) Time to reach the platform in the open pool task to
ensure animals are free of visual impairments for all injection groups, n = 27. Results from one-way ANOVAs were
conducted for each task. Data are presented as mean ±SEM (error bars). Each dot represents one mouse. ** p ≤ .001
Fisher’s LSD post-hoc analysis. RAWM = radial arm water maze
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CHAPTER FIVE:
DISCUSSION
This body of work has demonstrated the importance of evaulating age and genetic mutant
variants of tau in translational models of tauopathy. As researchers are still trying to gain a full
understanding of Alzheimer’s disease (AD) pathology to indentify critical periods for
interventions, animal models are cruical to help achieve these goals. Therefore the evaluation of
the current animal models are imperitive to ensure their translational ability to clinical cases.
The present work showed evidence of age effects in both a transgenic and three viral
models of tauopathy. For study one, markers of tauopathy, inflammation, and neurodegeneration
differ through the lifecourse. These findings are an extension of the early seminal age-series
examinations of the model conducted by others (Ramsden et al., 2005; Santacruz et al., 2005).
Dickey et al. (2009) demonstated that not all markers in the rTg4510 line change in linear trends
in an age-series examination up to ten months of age. This study lends support for non-linear
modeling for indicators of pathology at ages older than those examned in Dickey et al. (2009). It
is important to understand how these markers of tauopathy and tauopathy-related pathology
differ across age to advanced ages, to adequately provide a robust examination of the model.
In addition to observing accumulation of pathology with age in the transgeic model, we
also demonstrated that the age when tau pathology was initatied also influenced the extent of
tauopathy. The viral modeling of tauP301L across young, middle-aged, and old mice shows a clear
effect of the age of onset. All the tauP301L injected mice had evidence of tauopathy, but the old
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animals that had a significantly greater amount of neurofibrillary tau tangles (NFTs). Clinical
evidence has demonstrated that pathology can begin decades before the onset of clinical
symptoms that usual manifest in older adulthood (Villemagne et al., 2008). This highlights the
clinical relevance of inducing pathology at the ages of increased risk for clinical disease
compared to transgenic models, which express an abundance of pathology at very early ages in
the life course.
It is important to not only to examine the effect of the age at tauopathy onset, but it is
also impairative to evaulate the various forms of tau to induce tauopathy. The present work
compared the viral models using tauP301L, tauR406W, and tauwild-type in middle aged (12 month)
mice. These comparisons evidenced that the tauR406W failed to demonstrate a substantial model of
tauopathy. This mutation is known to have a slower pathological changes in comparison to other
mutations (Van Swieten et al., 1999). This is consistent with the findings decribed here. The
pathology observed in the viral model of tauP301L was comparable to that in the transgenic
rTg4510 model that shows pathological increases in detergent insoluble fractions and NFTs that
are readily apparent. NFTs are a hallmark pathology of AD , so their presence in this model of
tauopathy highlights its relevance. On the other hand, tauwild-type injection produced changes in
soluble tau that are accompanied by substantial reductions in hippocampal volume. Because
tauwild-type is associated with atrophy, it demonstrates a clear pathological event is taking place
One important relevant cause may be tau oligomers. Early events in the progression of tauopathy
should be further examined to understand the critical periods where these changes are occuring
(Lasagna‐Reeves et al., 2012; Maeda et al., 2006; Shafiei et al., 2017).
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Limitations
No body of work is without limitations. This current dissertation has several limiations
that included, first and foremost, the lack of the evaulation of tau oligomers. Furthermore, this
body of work present evidence of a linear increase of NFTs, but other tau variants vary or even
decrease with age. A current assumption is that ghost tangles can remain in tissue after neuronal
death as a tombstone and could represent a toxic tau form. Evidence for ghost tangles was not
evaluated. Therefore, currently we are not able to evaluate whether ghost tangles may be toxic.
There are many tau variants that remain to be assessed in this model, including conformationspecific antibodies, tau phosphorylated at epitopes linked to Alzheimer’s disease, such as
phospho-tau181, and tau with other post-translational modifications, such as truncations or
acetylation. Assessment of tau oligomers and other tau variants in future experiments could
contribute to understanding how tau variants affect neurodegeneration.
Limitations that are specific to study one includes the lack of behavioral measures.
Behavorial assessments were not performed because the rTg4510 line has been well
characterized and demonstrated to exhibit cognitive impairments on a varitey of tasks that
include the radial arm water maze and novel object recognition among others (Brownlow et al.,
2014; Joly-Amado et al., 2016; Ramsden et al., 2005; Santacruz et al., 2005). While cognitive
impairments have been documented, the current work did not extend the findings to include
behavioral measures, in part because these develop very early (4-6 months) in the course of tau
accumulation. Work from Gamache et al. (2019) questioned the utility of the rTg4510 model, by
demonstrating that the insertation of the P301L mutation can disrupt several genes that could
impact the phenotype. However, the scope of the study was to understand a long-term age series
examination of pathological indicators across the life course. This study was not able to examine
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any impact caused by the potential gene disruption caused by the P301L transgene insertion. Yet,
it is important to note that the changes in insoluble tau and NFTs were similar to the viral model
of tauP301L.
Limitations for studies two and three are the lack of viral timecourse examination after
tau viral injections. Given the severe hippocampal atrophy in the tauwild-type group, a time point
shorter than four months might allow discrimination of more subtle group differences. On the
other hand, a longer post-injection time points could allow effects of tau R406W to manifest. In
addition, more detailed examination of important activated microglia changes could be pursued.
The significant differences observed for age and tau variant injection for MHCII does provide
support for differences in microglia activation.
Specifically in regards to study two, there was a large, unexpected amount of animals that
were not able to swim through the four days of testing in the water maze. This caused a reduction
in sample size and may have hindered detection of additional important differences.
Furthermore, with aging animals, it is expected for some animals to have health concerns, but
there were more animals than anticipanted to have a health concerns in this series of
C57BL/6Nia mice (i.e., eye problems, seizures).
Future directions
To take the current findings and try to bridge the gap of the current limitions, future
directions include the examination of any evidence of tau oligomers in the through the
examination of ELISA or dot blot assays (Kanaan et al., 2016) in tau viral studies. Tau oligomers
are hypothesized to induce neurotoxicity. Because argyrophilic tau aggregates are not
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responsible for neurotoxicity in the tau wild-type injected mice, it is possible that more tau
oligomers are produced in this condition.
Furthermore, to examine if any of the silver positive NFTs are evidence of ghost tangles,
histological staining should be conducted on rTg4510 tissues to identify any ghost tangles. To
identify the evidence of any ghost tangles would provide a complete evaulation of the model. In
addition, to having a more detailed understanding of the rTg4510 model, evidence of ghost
tangles may provide an explain why some markers of tauopathy decrease with age.
To provide more detailed examinations of viral models of tauopathy, additional markers
of reactive microglia should be examined. This may provide additional validation of this model.
Finally, RAWM behavioral assessments with older mice should be evaluated to aid in the
determination of what age that mice start to experience distruptions in their ability to swim.
Alternative performance strategies could be considered such as fewer trials, longer inter-trial
intervals or warmer water temperature to improve retention of aged mice. This is needed to
reduce the likelihood of animals being excluded from future studies, or to establish increased
numbers required to retain full statistical power.
The development of a viral delivery based model, such as described here, will provide
researchers with an alternative to transgenic models. Transgenic models suffer from inability to
initiate pathology at the age of risk. The strong AAV-based model described here recapitulates
qualities of human disease. Its use will allow future researchers to explore mechanisms of
neurodegeneration and to explore the translational potential of experimental therapeutics for
Alzheimer’s disease and other tauopathies.
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Implications for Health and Well-Being for Older Adults
To date there are no safe and effective treatments to reverse or halt the pathology that
contributes to AD (Cummings et al., 2019; Cummings et al., 2014). However, previous research
has clearly demonstrated that tau is more closely related to cognitive declines and neuronal loss
associated with the disease (Bejanin et al., 2017; Gordon et al., 2018). Because of this
relationship, this body of work was aimed at examining various models of tauopathy and their
abilities to recapitulate features of human disease. Age remains the greatest risk factor for
tauopathy and needs to be represented in a model for identifying markers for early detection and
the treatments of AD. The present work examined age in two models of tauopathy. The
transgenic model demonstrates an important shift in tau from the soluble, or less harmful forms
of tau, to insoluble aggregates that are more progressed formations of pathology that can
contribute to neuronal loss. This shift occurs around one year of age. Identifying this critical age
period is important as this allows research to investigate the key changes for this pathological
shift at the appropriate age. Identifying these key changes are critical as they can aid in the
identification of early biomarkers and even new drug treatments for tau.
In addition, the viral modeling of tau allows for a model that is more relevant to human
cases. For most AD diagnoses, pathology begins accumulating in mid to late life, not in early life
and adulthood as demonstrated in transgenic animal models. Therefore, having a model that
allows for the onset of the disease to occur in ages that are comparable to human cases provides
important information to animal models. The aging immune system has a clear impact on the rate
and formation of pathological tau, so to study this pathology, age of disease onset is a critical
factor (Franceschi & Campisi, 2014; Joly-Amado et al., 2020; Lee et al., 2010; Licastro et al.,
2005). Not only does implementing a later age of onset allow for a more meaningful display of
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tau pathology but allows for the investigation of an aging immune system on the rate and
formation of pathology. This is helpful as there are potential pathways in the aging immune
system that may be more beneficial to target for drug treatments to reduce or halt pathological
tau formations. Furthermore, having an aging model of pathology is more beneficial when
administering drug treatments, as individuals that would receive treatments would be older in
clinical settings and would be potentially impacted differently than younger individuals.
Because there are no treatments for AD, it is imperative for the animal studies to
investigate the critical changes in tau and the immuune system to identify key changes for the
preventation and treatment of the disease. As demonstrated in this body of work, animal models
are able to mimic features of clinical AD and provides the foundation for the additional work to
aid in the identification of early changes. The examination of early changes have the ability to
discover important early key biomarkers for the early detection of the disease as well as drug
treatment targets that will allow for the discovery of a treatment that has the ability to aid the
milllions of individuals afflicted by AD.
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Tauopathy and Degeneration
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Alzheimer's Association
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The Institutional Animal Care and Use Committee (IACUC) reviewed your application
requesting the use of animals in research for the above-entitled study. The IACUC
APPROVED your request to use the following animals in your protocol for a one-year
period beginning 2/22/2017:
Mouse: Tg4510 = F1 of [FVB-Tg(TRE-P301L 540 tau)] x
[129S-Tg(Camk2a-tTA)
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Service Policy on
Humane Care and Use of Laboratory Animals (PHS Policy), the Guide for the Care and Use of
Laboratory Animals, 8th Edition (the Guide), and the Guide for the Care and Use of
Agricultural Animals in Research and Teaching, 3rd Edition (Ag Guide).
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